Finex Pulse • Market Signal Briefing

Details	Saved	Published	Title	Source	Tickers
	2025-11-03 08:20 4mo ago	2025-11-03 03:01 4mo ago	Lantheus Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH	stocknewsapi	LNTH
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Lantheus Holdings, Inc. ("Lantheus " or "the Company") (NASDAQ: LNTH ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of LNTH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: February 26, 2025 to August 5, 2025 DEADLINE: November 10, 2025 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Lantheus overstated the market leadership of Pylarify while competitors were eroding its market position. The weakness of Pylarify was made apparent by significant declines in sales throughout 2025. Based on these facts, Lantheus' public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate . NEXT STEPS FOR SHAREHOLDERS : Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 Email: [email protected] SOURCE DJS Law Group LLP
	2025-11-03 08:20 4mo ago	2025-11-03 03:01 4mo ago	Headwater Exploration: Costs Continue To Decline As Exploration Success Continues	stocknewsapi	CDDRF
Analyst’s Disclosure:I/we have a beneficial long position in the shares of CDDRF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Disclaimer: I am not an investment advisor, and this is not a recommendation to buy or sell a security. Investors are recommended to read all of the company's filings and press releases, as well as do their own research to determine if the company fits their own investment objectives and risk portfolios. I may buy more shares without any further notice. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
	2025-11-03 08:20 4mo ago	2025-11-03 03:02 4mo ago	CrowdStrike 2025 European Threat Landscape Report: Ransomware Hits Region at Record Pace	stocknewsapi	CRWD
- Europe ranks as second largest eCrime target globally amid intensifying “Big Four” nation-state activity AUSTIN, Texas--(BUSINESS WIRE)--Fal.Con Europe 2025, Barcelona-- CrowdStrike (NASDAQ: CRWD) today released the 2025 European Threat Landscape Report, revealing that European organizations accounted for nearly 22% of global ransomware and extortion victims — second only to North America. Ransomware operations are moving faster than ever, with CrowdStrike observing adversary groups like SCATTERED SPIDER increasing ransomware deployment speed by 48%, with the average attack now taking just 24 hours. Adversaries operating in and targeting Europe benefited from underground marketplaces commoditizing services like Malware-as-a-Service, initial access brokerage, and phishing toolkits. In parallel, state-sponsored adversaries from Russia, China, North Korea, and Iran expanded regional targeting across industries, reflecting the growing convergence of eCrime and geopolitical threats. European Threat Landscape Report Highlights: Based on frontline intelligence from CrowdStrike Counter Adversary Operations, which tracks more than 265 named adversaries, the report reveals: Ransomware Attacks Reach Historic Highs: Since January 1, 2024, more than 2,100 victims across Europe were named on extortion leak sites. The U.K., Germany, France, Italy, and Spain were the most targeted nations, with 92% of cases involving file encryption and data theft. Fueling Big Game Hunting operations, 260 initial access brokers advertised to over 1,400 European organizations. Russia and North Korea Escalate Threats: Russia-nexus actors continued to target Ukraine conducting credential phishing, intelligence collection, and destructive operations targeting government, military, energy, telecom, and utilities. DPRK-nexus actors expanded targeting of European defense, diplomatic, and financial institutions, combining espionage with cryptocurrency theft to advance strategic interests. Underground Ecosystems Evolve: English- and Russian-language forums — including BreachForums, a successor to RaidForums whose administrators were linked to actors in France and the U.K., remain central to Europe’s eCrime ecosystem, enabling the exchange of stolen data, malware, and criminal services. Platforms like Telegram, Tox, and Jabber facilitated collaboration, recruitment, and monetization among threat actors. Physical Crime Goes Digital: Violence-as-a-Service emerged as a growing threat across Europe, with threat actors using Telegram-based networks to coordinate physical attacks, kidnappings, and extortion tied to cryptocurrency theft. Groups connected to “The Com” ecosystem and hybrid adversaries like RENAISSANCE SPIDER are bridging cyber and physical operations, offering payments for sabotage, arson, and targeted violence. China Concentrates its Modus Operandi: Chinese state-sponsored adversaries targeted industries in 11 countries, exploiting cloud infrastructure and software supply chains to steal intellectual property. Persistent campaigns focused on healthcare and biotechnology, with VIXEN PANDA emerging as the most prolific threat to European government and defense entities. Iranian Operations Expand to Europe: IRGC-linked actors ramped up phishing, hack-and-leak, and DDoS campaigns against the U.K., Germany, and the Netherlands. HAYWIRE KITTEN claimed responsibility for a DDoS attack against a Dutch news outlet, while multiple Iran-nexus actors masqueraded as hacktivists to obscure state-sponsored espionage efforts. “The cyber battlefield in Europe is more crowded and complex than ever,” said Adam Meyers, head of Counter Adversary Operations at CrowdStrike. “We’re seeing a dangerous convergence of criminal innovation and geopolitical ambition, with ransomware crews using enterprise-grade tools and state-backed actors exploiting global crises to disrupt, persist, and conduct espionage. In this high-stakes environment, intelligence-led defense powered by AI and guided by human expertise is the only combination designed to stop cyber threats.” Download the full 2025 European Threat Landscape Report to gain valuable insights and mitigation strategies to stay ahead of cyber adversaries in Europe’s increasingly complex threat landscape. About CrowdStrike CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world’s most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data. Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting and prioritized observability of vulnerabilities. Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity and immediate time-to-value. CrowdStrike: We stop breaches. Learn more: https://www.crowdstrike.com/ Follow us: Blog \| X \| LinkedIn \| Instagram Start a free trial today: https://www.crowdstrike.com/trial © 2025 CrowdStrike, Inc. All rights reserved. CrowdStrike and CrowdStrike Falcon are marks owned by CrowdStrike, Inc. and are registered in the United States and other countries. CrowdStrike owns other trademarks and service marks and may use the brands of third parties to identify their products and services. More News From CrowdStrike Back to Newsroom
	2025-11-03 08:20 4mo ago	2025-11-03 03:02 4mo ago	FLR Investors Have Opportunity to Lead Fluor Corporation Securities Fraud Lawsuit with the Schall Law Firm	stocknewsapi	FLR
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fluor Corporation ("Fluor" or "the Company") (NYSE: FLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2025 and July 31, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before November 14, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Fluor suffered increased costs on multiple major projects due to price increases, delays, and subcontractor design errors. The Company's financial performance was impacted by these issues along with a reduction in capital spending by customers. The Company's financial guidance was unrealistic and it overstated the strength of its risk mitigation strategy. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Fluor, investors suffered damages. Join the case to recover your losses The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq., www.schallfirm.com Office: 310-301-3335 [email protected] SOURCE The Schall Law Firm
	2025-11-03 08:20 4mo ago	2025-11-03 03:02 4mo ago	India now incurs higher U.S. tariffs than China. What does it say about Trump's foreign policy?	stocknewsapi	INDA
De-escalation in tensions between China and the U.S. after their leaders met in South Korea last Thursday stands in stark contrast to the chill in Washington-New Delhi relations, with India now subject to higher U.S. tariffs than Beijing. Experts said that the strategic relationship between India and U.S. built over two decades has substantially eroded. Atman Trivedi a partner and lead of the South Asia Practice at DGA-Albright Stonebridge Group said trust between the two countries "could take years rebuild." Steep tariffs, $100,000 fee for H1B visas, and U.S. President Donald Trump's repeated claims of having brokered a ceasefire between India and Pakistan are among issues that have led to deterioration of ties between New Delhi and Washington in recent months, according to experts. "President Trump evidently does not value India as a partner in balancing China as much as the previous presidents," said Raymond Vickery Jr., senior associate and chair on India and emerging Asia Economics at Center for Strategic and International Studies. The U.S. foreign policy from President Bill Clinton until recently, including Trump's first term as the president, had consistently valued "democratic India over autocratic China," he said, adding that the approach toward India has now shifted from one of strategic altruism to "transactionalism." Meanwhile, ties between the U.S. and China appear to be on the mend. In a post on Truth Social on Saturday, Trump said "My G2 meeting President Xi of China was a great one for both of our countries" adding that it would lead to "everlasting peace and success." Shortly after, Pete Hegseth, U.S. secretary of defense, said on X that China and the U.S. had agreed to set up "miliary-to-military channels to deconflict and deescalate" any problems. Trump and Chinese President Xi Jinping reached a trade truce in a high-stakes meeting in South Korea on Thursday which saw Washington cutting tariffs on Beijing related to fentanyl to 10% from 20%, reducing the overall rate on Chinese goods to around 47%. China now pays a lower tariff than India. In August the U.S. imposed 50% tariffs on India including secondary duties of 25% for its purchase of Russian oil. India has called the move "unfair, unjustified and unreasonable," while has called U.S. trade ties with India "a totally one-sided disaster!" "At the leader-level, the chemistry is missing for now, and the impact of this disconnect on the U.S.-India relationship probably cannot be overstated," Trivedi added. During his Asia trip last week, while addressing corporate leaders at Asia-Pacific Economic Cooperation summit in South Korea, Trump said he threatened India and Pakistan with 250% tariffs unless they stopped hostilities. An attack by militants in the Indian-controlled region of Kashmir in April killed 26 civilians. India accused Pakistan and launched a military strike, resulting in a four-day conflict that threatened to explode into a broader war fueled by decades of tensions between the two countries. "The strategic relationship between India and the U.S. has been under strain this year not just because of tariffs, but also because of Washington's posture in the conflict with Pakistan and the apparent warming of [U.S.] ties with Pakistan's military," said Alexandra Hermann, head of Southeast Asia Research at Oxford Economics. Trump's claims are being picked up by Modi's political opponents including the leader of opposition Rahul Gandhi. Modi is "scared" of U.S. President Donald Trump, Gandhi reportedly said on Sunday in a political rally in Bihar. Hermann added that now the challenge for India would be to find its position between two economic superpowers. "While New Delhi stands to benefit from greater access to U.S. demand, its dependence on China is unlikely to diminish in the near term given the still-extreme uncertainty around trade policy and the costs of relocating supply chains," she said. Keeping aside strained trade ties, U.S. and India on Friday signed a 10-year "Framework for the US-India Major Defence Partnership." Hegseth said on X that the two countries were improving "coordination, info sharing, and tech cooperation," while his Indian counter Rajnath Singh said the partnership between U.S. and India was "critical for ensuring a free, open and rules-based Indo-Pacific region." Experts warn if U.S. sticks with its transactional approach toward India, it will drive the two further apart, compromising strategic interests of both. "The Trump policy will push India further toward Russia, the Global South, and even China. This will not be in the interests of either India or the US," said Vickery Jr. from CSIS.
	2025-11-03 08:20 4mo ago	2025-11-03 03:04 4mo ago	Flux Power: Capital Requirements And Nasdaq Delisting Threat Addressed - Buy (Rating Upgrade)	stocknewsapi	FLUX
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in FLUX over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
	2025-11-03 08:20 4mo ago	2025-11-03 03:06 4mo ago	Capita to use AI as part of Samsung call centre contract extension	stocknewsapi	SSNLF
Capita PLC (LSE:CPI) has won contract extensions for its call centre business with Samsung Electronics (KRX:005930) consumer and business customers in the UK, answering calls, emails and social media queries from people who have bought mobile phones, TVs and other products from the Korean colossus. The outsourcer will "deliver impactful transformation", it said, including a pilot of its Agent Suite generative AI platform that supports contact centre agents, such as by summarising calls, suggesting responses, or automating routine queries. Capita, which has worked with Samsung UK since 2011 and servicews businss customers since 2016, said its use of AI will "provide a more personalised and proactive service, improving the customer and colleague experience", which it said "aligns with and supports Samsung’s mission to inspire consumers to adopt the company’s innovative technology". Corinne Ripoche, CEO of Capita's Experience division, said: "These new contracts further strengthen our 14-year partnership with Samsung, and we will be prioritising innovation and quality to ensure seamless, efficient, and valuable experiences for Samsung and their customers. "I am especially excited that we will be driving these experiences via the increased application of technology and AI."
	2025-11-03 08:20 4mo ago	2025-11-03 03:07 4mo ago	Anglo Asian strikes copper sales deal with Trafigura at Demirli mine	stocknewsapi	AGXKF CPER JJC
Anglo Asian Mining Plc (LSE:AAZ, OTC:AGXKF) has signed a sales agreement with commodities trader Trafigura for copper concentrate produced at its Demirli mine in Karabakh, Azerbaijan. The deal includes a revolving prepayment facility of up to $25 million, giving the miner access to working capital as production ramps up. The company said it had now received the necessary government licences to operate the Demirli processing plant and permission to use the existing tailings dam for up to 12 months while a second facility is built. Its operating lease for the plant began on 1 October. The agreement with Trafigura, which the Azerbaijani government has approved, marks a key step in bringing Demirli into full operation. The first sale of copper concentrate is expected to be completed by mid-November. Chief executive Reza Vaziri said the licences and sales deal were major milestones for the business. “I am delighted that we have received all the relevant licences to operate the plant and tailings dam at Demirli, an important milestone as the mine becomes fully operational and increasingly contributes to Group production,” he added. “The obtaining of all relevant licences together with the Trafigura sales contract enables us to commence copper concentrate sales now and deliver value from Demirli.” The Demirli mine is part of Anglo Asian’s wider push to expand its copper output alongside existing gold and silver operations in Azerbaijan, as the company aims to diversify and strengthen its production base.
	2025-11-03 08:20 4mo ago	2025-11-03 03:08 4mo ago	CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm	stocknewsapi	CYTK
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 27, 2023 and May 6, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before November 17, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Cytokinetics led investors to believe that it expected FDA approval on its NDA for aficamten in the second half of 2025. The Company failed to inform the market of material risks of its NDA not achieving approval based on its failure to submit a Risk Evaluation and Mitigation Strategy ("REMS"), which could delay the FDA's processing. The Company revealed on May 6, 2025, that it had multiple pre-NDA meetings with the FDA about safety and mitigation of risk but still chose to submit its NDA without a REMS. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Cytokinetics, investors suffered damages. Join the case to recover your losses The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq., www.schallfirm.com Office: 310-301-3335 [email protected] SOURCE The Schall Law Firm
	2025-11-03 08:20 4mo ago	2025-11-03 03:09 4mo ago	aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR	stocknewsapi	ATYR
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. On September 15, 2025, Reuters reported that, "aTyr Pharma said on Monday its experimental drug had failed to meet the main goal in a late-stage study testing it in patients with a type of lung disease known as pulmonary sarcoidosis, which impacts the lungs and lymph nodes." Based on this news, shares of aTyr traded down by more than 81% in morning trading on the same day. If you are a shareholder who suffered a loss, contact us to participate. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 Email: [email protected] SOURCE DJS Law Group LLP
	2025-11-03 08:20 4mo ago	2025-11-03 03:09 4mo ago	Apple: Muted Reaction To Strong Guidance	stocknewsapi	AAPL
SummaryApple delivered mixed Q4 results, with iPhone revenues missing estimates but strong Services and Mac performance supporting growth.AAPL's gross margin and operating income improved year-over-year, aided by a growing Services segment and help from the buyback.Guidance for 10% to 12% revenue growth in the holiday quarter exceeded analyst expectations, despite iPhone supply constraints. ozgurdonmaz/iStock Unreleased via Getty Images Last Thursday, we received fiscal fourth quarter results from technology giant Apple (AAPL) for its September-ending period. With shares of the company entering the report basically at an all-time high, expectations were elevated amidst Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Investors are always reminded that before making any investment, you should do your own proper due diligence on any name directly or indirectly mentioned in this article. Investors should also consider seeking advice from a broker or financial adviser before making any investment decisions. Any material in this article should be considered general information, and not relied on as a formal investment recommendation. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. Recommended For You
	2025-11-03 08:20 4mo ago	2025-11-03 03:14 4mo ago	BP to Sell Stakes in U.S Midstream Assets for $1.5 Billion to Sixth Street	stocknewsapi	BP
The energy company said it would sell stakes in assets which are operated by its U.S. onshore oil and gas business BPX in the Permian and Eagle Ford basins.
	2025-11-03 08:20 4mo ago	2025-11-03 03:15 4mo ago	HEALWELL AI Announces Strategic Divestments and Progression to a Pure-Play SaaS, Services and AI Business	stocknewsapi	HWAIF
November 03, 2025 3:15 AM EST \| Source: HEALWELL AI HEALWELL has divested its Polyclinic Family Medicine and Specialty Group of Clinics to WELL Health Clinic Network Inc. ("WELL Clinics"), who has been previously managing these clinics for HEALWELL since January 2024.HEALWELL has sold its interest in Mutuo Health Solutions Inc. ("Mutuo") to WELLSTAR Technologies Corp. ("WELLSTAR"), so it can better focus on its large enterprise healthcare software and AI business. Mutuo is primarily focused on selling solutions to doctors and clinics which aligns better with WELLSTAR's focus and leverages Mutuo as part of its Nexus AI platform.HEALWELL has formed a 50/50 clinical research joint venture with WELL Health Technologies Corp. The joint venture includes Bio Pharma Services Inc. and Canadian Phase Onward Inc. which will no longer be consolidated under HEALWELL. The joint venture will continue the strategic evaluation process to best support the growth opportunity in clinical research.Due to the non-arm's length nature of these transactions, HEALWELL formed a special committee of three directors to assess and approve these transactions, who relied on a fairness opinion from Doane Grant Thornton LLP.Together these transactions allow HEALWELL to become a pure-play digital SaaS, services and AI business, primarily focused on health systems and large enterprises globally with a revenue run rate of approximately $120 million annually and is profitable on an Adjusted EBITDA basis. Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, today announced that it has completed a series of strategic transactions (the "Transactions") with WELL Health Technologies Corp. ("WELL") and its subsidiaries, WELL Health Clinic Network Inc. ("WELL Clinics") and WELLSTAR Technologies Corp. ("WELLSTAR"), to streamline operations, accelerate clinical research, and focus on high-growth AI and software initiatives. The transactions include the sale of HEALWELL's Polyclinic Family Medicine and Specialty Clinics Group ("Polyclinic") to WELL Clinics, the sale of HEALWELL's interest in Mutuo Health Solutions Inc. ("Mutuo") to WELLSTAR, and the creation of a clinical research joint venture with WELL. The Transactions closed on November 1, 2025, following the satisfaction of customary conditions precedent, including receipt of required third-party consents and regulatory and exchange approvals. James Lee, CEO of HEALWELL, commented, "These transactions accelerate our evolution into becoming a pure-play, high-margin AI and SaaS software and services business focused on large enterprise customers globally. Our strategy is clear: HEALWELL is a preventative healthcare AI company that leverages advanced technology to connect and surface complex healthcare data, providing clinically validated tools that enhance both efficiency and accuracy." The Transactions are the result of a strategic review in which HEALWELL has explored strategic alternatives for its non-core businesses, including its clinical research and patient services business units as well as its SMB or provider-tech focused Mutuo business, with the goal of becoming a pure-play digital SaaS and services company focused on enterprise-grade data science and AI offerings for health systems globally. The Transactions enable HEALWELL to monetize non-core assets, streamline operations, and strengthen long-term strategic partnerships with WELL and WELLSTAR, and strengthen HEALWELL's balance sheet by adding approximately $9.4 million of cash upon closing. Sacha Gera, HEALWELL's Chief Operating Officer commented, "These transactions will allow us to place greater focus on integrating our industry leading and third party validated AI solutions with our healthcare software segment and obtain important synergies that will result in margin expansion and organic growth. Across all collaborations, we remain vendor-agnostic and committed to open standards, interoperability, and data portability to preserve customer choice and support a competitive ecosystem." Polyclinic transaction details: The sale of the Polyclinic business allows HEALWELL to focus on higher-growth AI and clinical research initiatives while enabling WELL Clinics to expand its network of patient care services. WELL Clinics has already been managing these clinics since January 2024. HEALWELL divested its family medicine and specialty clinic operations, comprising two clinics under the Polyclinic brand, with approximately 40 physicians, to WELL Clinics for an aggregate purchase price of: $1.2 million in cash at closing.Up to $1.2 million in earn-out expected to be paid in the first half of 2026. Mutuo transaction details: The divestiture of Mutuo enables HEALWELL to concentrate resources on its core digital healthcare solutions while Mutuo strengthens WELLSTAR's Nexus AI platform. HEALWELL is building category-leading AI solutions for public health and life sciences, while WELLSTAR advances digital enablement for healthcare providers and clinics in Canada. HEALWELL has sold its 58.66% interest in Mutuo to WELLSTAR, including its warrants and certain contractual rights, for: $8,212,400 in cash, subject to adjustments for debt and working capital.$615,930 of the purchase price have been held in a four-month general indemnity holdback to cover working capital adjustments and indemnity claims.HEALWELL's rights under certain agreements, including the Unanimous Shareholder Agreement for Mutuo, its warrants to acquire additional shares of Mutuo and its Strategic Alliance Agreement with Mutuo (including profit-sharing arrangements) have been assigned to WELLSTAR.Biopharma and Canadian Phase Onward transaction details: HEALWELL and WELL established a limited partnership to house the new joint venture, in which they each hold a 50% economic interest to advance clinical research initiatives. The joint venture for clinical research will continue to undertake its strategic evaluation process to best support the growth opportunity in clinical research. The joint venture for clinical research is currently positioned to capitalize on late-stage clinical research opportunities in Canada, leveraging clinic networks and expertise for higher-margin, more impactful clinical trials. Key elements of the joint venture agreement included: HEALWELL contributed: Bio Pharma Services Inc. and Canadian Phase Onward Inc., taking back 3,000,000 Class A LP Units of the joint venture limited partnership, valued at $3,000,000.WELL contributed: A $3,000,000 capital commitment, receiving 3,000,000 Class B LP Units of WELL Research. An initial capital call of $500,000 has been made at closing, with further calls based on the cash needs of the joint venture.Additional Information on the Transactions: WELL Clinics, WELLSTAR and HEALWELL are each controlled, directly or indirectly, by WELL. As a result, the Transactions are related party transactions Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The terms of the Transactions were negotiated by the Company's management, with the Company and its counterparties, WELL, WELL Clinics and WELLSTAR (the "Counterparties") represented by separate legal counsel. To supervise and evaluate the negotiation of the Transactions, and to consider potential alternatives, the board of directors of the Company formed a special committee on September 10, 2025, consisting of three directors with no interest in the Transactions or in any of the Counterparties. In carrying out its mandate, the special committee received information and presentations from the Company's management and legal counsel, as well as a fairness opinion from Doane Grant Thornton LLP which concluded, based on standard qualifications and assumptions, that each of the Transactions (which were evaluated separately) was fair to the Company and its shareholders. The special committee unanimously recommended the Transactions to the board of directors for approval by written resolutions dated September 30, 2025 and October 31, 2025, and the board of directors unanimously approved the Transactions on October 31, 2025, with interested directors declaring their interest in the Transactions and recusing themselves from the board's voting or deliberations. HEALWELL is exempt from the formal valuation and minority shareholder approval requirements under MI 61-101 as the aggregate fair market value of the Transactions does not exceed more than 25% of the market capitalization of HEALWELL. The Company's directors and officers are not aware of any valuations obtained with respect to any of the subject matter of the Transactions in the last 24 months. The Company did not file a material change report 21 days in advance of implementing the Transactions as the terms of the Transactions were not settled. In addition to the requirements under MI 61-101, the Transactions were also subject to approval under Section 501 of the TSX Company Manual. The Company obtained a conditional approval from the TSX in respect of the Transactions prior to closing. The TSX has not considered or made any determination on the merits of the proposed Transactions and have neither approved nor disapproved of this press release. James Lee Chief Executive Officer HEALWELL AI Inc. About HEALWELL AI HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit https://healwell.ai/. Forward-Looking Statements Certain statements in this press release, constitute "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including statements about the anticipated accounting treatment of certain of the divested assets, the potential for future payments of contingent consideration in respect of some of the Transactions, and the plans for certain of the divested assets and their potential longer term benefits ; and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements are often, but not always, identified by words or phrases such as "progression", "continue", "to become", "accelerate", "strategy", "enable", or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occuror be achieved, or the negative of any of these terms. Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward-looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: HEALWELL's ability to maintain and leverage its relationships with its commercial partners; the continued adoption of the software, tools and solutions created by HEALWELL and its subsidiaries; the stability of general economic and market conditions; sufficiency of working capital and access to financing; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; technologies working as intended or at all; trends in customer growth and the adoption of new technologies in the industry; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated March 31, 2025, which is available under HEALWELL's SEDAR+ profile at www.sedarplus.ca. The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272919
	2025-11-03 08:20 4mo ago	2025-11-03 03:16 4mo ago	AXA SA (AXA:CA) Q3 2025 Sales Call Transcript	stocknewsapi	AXAHF AXAHY
AXA SA (AXA:CA) Q3 2025 Sales Call October 31, 2025 4:00 AM EDT Company Participants Anu Venkataraman - Group Chief Strategy Officer & Head of Investor Relations Alban Nesle - Group Chief Financial Officer Conference Call Participants David Barma - BofA Securities, Research Division Michael Huttner - Joh. Berenberg, Gossler & Co. KG, Research Division Andrew Baker - Goldman Sachs Group, Inc., Research Division Thomas Bateman - Mediobanca - Banca di credito finanziario S.p.A., Research Division Farooq Hanif - JPMorgan Chase & Co, Research Division Andrew Crean - Bernstein Autonomous LLP Dominic O''mahony - BNP Paribas, Research Division Presentation Anu Venkataraman Group Chief Strategy Officer & Head of Investor Relations Good morning, and thank you for joining AXA's 9 Month 2025 Activity Indicators Call. Our Group CFO, Alban de Mailly Nesle, will walk through the highlights from the press release that we published last night, after which we'll be ready to take your questions. With that, I turn it over to Alban. Alban Nesle Group Chief Financial Officer Thank you, Anu and good morning to all of you. Thank you for joining the call today. So let me start with the key highlights of -- on 9 months '25. Overall, we delivered a solid performance with total revenues increasing by 7% to EUR 89 billion. This reflects the strength of our franchise, which, as you know, is well diversified by line of business with 60% in P&C and 40% in Life & Health and is also balanced between B2B and B2C. All our geographies are delivering a consistent execution of our organic growth strategy, which is one of the key levers of our current plan. We continue to operate at a high level of capital with a Solvency II ratio at 222%. In the quarter, the group's financial strength was further affirmed by the decision from Moody's to upgrade its ratings from Aa3 to Aa2. Recommended For You
	2025-11-03 07:20 4mo ago	2025-11-03 01:45 4mo ago	Shake Shack Surges on Earnings Beat: Are Shares a Buy?	stocknewsapi	SHAK
Shake Shack shares are up after the company handily beat earnings and revenue estimates in Q3. Shares of Shake Shack (SHAK +5.61%) rose 5% in intraday trading on Thursday as the company's well-received third-quarter earnings report pushed shares higher. The company reported revenue of $367.4 million for the quarter, up 15.9% year over year. Net income was $12.5 million, while its restaurant-level profit margin ticked up to 22.8%. Just as important as the improved numbers was the expectations game. Shake Shack's earnings growth beat analysts' estimates by 16.1%, while its revenues beat expectations by 1%. Today's Change ( 5.61 %) $ 5.13 Current Price $ 96.51 Shake Shack also opened 13 company-owned stores, adding to the seven licensed locations opened in the quarter. The company forecasts opening 90 to 110 company-owned and licensed locations in fiscal 2026 as part of its push to nearly quintuple its store count to 1,500 locations in the years ahead. So, from rising earnings and revenue to new store openings and growing margins, it was a triumphant earnings report. But there are two big reasons investors should hold off on buying shares for now. Macroeconomic winds are pinching the fast-casual sector This earnings season, the CEOs of Domino's Pizza, Starbucks, Chipotle, and a handful of other fast-casual dining companies have lamented challenging macroeconomic environments and pinched consumer spending as headwinds for their companies. According to the Center for Economic Policy Research, Americans' spending on fast food plateaued in 2024 and continued to stand still into 2025, despite growing at an average clip of 5.4% in 2021 through 2023. In fact, spending in August was less than 0.1% higher than it had been in December 2023. How much worse can it get? Shake Shack is forecasting beef inflation in the mid-teens for the second half of 2025, and beef is the biggest part of its commodity basket. It also expects beef inflation to continue into 2026. And with droughts worldwide leading to historically low cattle supply, analysts say the problem could persist into 2030. "We have pricing power," Rob Lynch, Shake Shack's CEO, said in Wednesday's earnings conference. For the last 19 quarters now, that's been true. Shake Shack has now grown same-store sales for every quarter since Q4 2020, despite having raised prices repeatedly during that time frame. But at some point, the triple whammy of rising inflation caused by tariffs, inflation caused by lower interest rates, and ongoing beef inflation triggered by drought may catch up to this company, especially if the economy continues to slow down, as many analysts are forecasting. Here's a fun fact: Since Shake Shack went public in January 2015, America's unemployment rate has never been below 5.7%, except for the anomalous 18-month period during COVID-19 lockdowns, when many millions of people received thousands of dollars in stimulus checks. Unemployment has been on an uptick in recent months and now stands at 4.3%. We don't know how many jobs were added last month because of the government shutdown, but the last report from the Bureau of Labor Statistics showed just 22,000 jobs created for all of August. If unemployment surges over the next few months (or if it's surging now and economists are unaware due to the lack of data), then Shake Shack could be tested in a way it never has been as a public company. Even a terrific company can be overvalued After its post-earnings rally, Shake Shack's price-to-earnings ratio stands at 94. That's triple the S&P 500 average of 31 and suggests that shares are approaching nosebleed valuation levels. What about by other metrics? Shake Shack's price-to-earnings-to-growth (PEG) ratio can offer a sense of how shares are valued relative to the rate of earnings growth. Shake Shack has a PEG ratio of 2.21, which also suggests overvaluation, as stocks with PEG ratios below one are generally thought of as being in value territory or close to it. For context, the high-flying semiconductor company Nvidia (NVDA 0.04%) has a PEG ratio of exactly 1, with a price-to-earnings ratio of 57, barely half of Shake Shack's. One big difference in the two companies' valuations is that Nvidia is growing earnings far faster at 59.2% year over year, compared to 16.1% year-over-year growth for Shake Shack. While Shake Shack is growing earnings, revenue, and margins at a respectable clip, its shares are priced as if it were growing them at a breakneck pace, which it isn't. When considering the macroeconomic headwinds that may get worse before they get better, it's clear that Shake Shack has more downside risk than upside potential in the short term. Its extravagant valuation tilts the odds against investors buying shares today.
	2025-11-03 07:20 4mo ago	2025-11-03 01:45 4mo ago	WPP PLC (NYSE: WPP) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds WPP plc Investors of Upcoming Deadline	stocknewsapi	WPP
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds WPP plc (“WPP” or the “Company”) (NYSE: WPP) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of WPP plc (NYSE: WPP)?Did you purchase your shares between February 27, 2025 and July 8, 2025, inclusive?Did you lose money in your investment in WPP plc? If you purchased or acquired WPP common stock, and/or would like to discuss your legal rights and options please visit WPP plc Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected]. A lawsuit was filed in the United States District Court for the Southern District of New York who purchased or acquired the common stock of WPP between February 27, 2025 and July 8, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers. According to the lawsuit, Defendants made misrepresentations concerning WPP’s media arm; notably, that it was not equipped to handle ongoing macroeconomic challenges while competing effectively. If you wish to serve as lead plaintiff for the Class, you must file papers by December 8, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years. ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information: Peter Allocco Investor Relations Manager Bernstein Liebhard LLP https://www.bernlieb.com (212) 951-2030 [email protected]
	2025-11-03 07:20 4mo ago	2025-11-03 01:45 4mo ago	JAMES HARDIE INDUSTRIES PLC (NYSE: JHX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds James Hardie Industries plc Investors of Upcoming Deadline	stocknewsapi	JHX
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds James Hardie Industries plc (“James Hardie” or the “Company”) (NYSE: JHX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of James Hardie Industries plc (NYSE: JHX)?Did you purchase your shares between May 20, 2025 and August 18, 2025, inclusive?Did you lose money in your investment in James Hardie Industries plc? If you purchased or acquired James Hardie common stock, and/or would like to discuss your legal rights and options please visit James Hardie Industries plc Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected]. A lawsuit was filed in the United States District Court for the Northern District of Illinois on behalf of investors (the “Class”) who purchased or acquired the common stock of James Hardie between May 20, 2025 and August 18, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers. According to the lawsuit, Defendants misrepresented that the Company’s North America Fiber Cement segment remained strong despite the challenging market environment. If you wish to serve as lead plaintiff for the Class, you must file papers by December 23, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years. ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information: Peter Allocco Investor Relations Manager Bernstein Liebhard LLP https://www.bernlieb.com (212) 951-2030 [email protected]
	2025-11-03 07:20 4mo ago	2025-11-03 01:45 4mo ago	MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline	stocknewsapi	MLTX
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)?Did you purchase your shares between March 10, 2024, and September 29, 2025, inclusive?Did you lose money in your investment in MoonLake Immunotherapeutics? If you purchased or acquired MoonLake common stock, and/or would like to discuss your legal rights and options please visit MoonLake Immunotherapeutics Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected]. A lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors (the “Class”) who purchased or acquired the common stock of MoonLake between March 10, 2024, and September 29, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers. According to the lawsuit, Defendants made misrepresentations concerning the Company’s sole drug candidate, sonelokimab (SLK), which was promoted as superior to competing monoclonal antibody drugs. If you wish to serve as lead plaintiff for the Class, you must file papers by December 15, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years. ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information: Peter Allocco Investor Relations Manager Bernstein Liebhard LLP https://www.bernlieb.com (212) 951-2030 [email protected]
	2025-11-03 07:20 4mo ago	2025-11-03 01:45 4mo ago	BAXTER INTERNATIONAL INC. (NYSE: BAX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Baxter International Inc. Investors of Upcoming Deadline	stocknewsapi	BAX
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Baxter International Inc. (NYSE: BAX)?Did you purchase your shares between February 23, 2022, and July 30, 2025, inclusive?Did you lose money in your investment in Baxter International Inc.? If you purchased or acquired Baxter common stock, and/or would like to discuss your legal rights and options please visit Baxter International Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected]. A lawsuit was filed in the United States District Court for the Northern District of Illinois on behalf of investors (the “Class”) who purchased or acquired the common stock of Baxter between February 23, 2022, and July 30, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers. According to the lawsuit, Defendants made misrepresentations by portraying its Novum IQ Large Volume Pump, a device used for the controlled delivery of intravenous fluids, as safe, while concealing systemic issues that put patients at risk of severe injury and death. If you wish to serve as lead plaintiff for the Class, you must file papers by December 15, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years. ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information: Peter Allocco Investor Relations Manager Bernstein Liebhard LLP https://www.bernlieb.com (212) 951-2030 [email protected]
	2025-11-03 07:20 4mo ago	2025-11-03 01:45 4mo ago	AVANTOR, INC. (NYSE: AVTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Avantor, Inc. Investors of Upcoming Deadline	stocknewsapi	AVTR
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Avantor, Inc. (“Avantor” or the “Company”) (NYSE: AVTR) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Avantor, Inc. (NYSE: AVTR)?Did you purchase your shares between March 5, 2024, and October 28, 2025, inclusive?Did you lose money in your investment in Avantor, Inc.? If you purchased or acquired Avantor common stock, and/or would like to discuss your legal rights and options please visit Avantor, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected]. A lawsuit was filed in the United States District Court for the Eastern District of Pennsylvania on behalf of investors (the “Class”) who purchased or acquired the common stock of Avantor between March 5, 2024, and October 28, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers. According to the lawsuit, Defendants made misrepresentations concerning the Company’s competitive positioning. If you wish to serve as lead plaintiff for the Class, you must file papers by December 29, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years. ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information: Peter Allocco Investor Relations Manager Bernstein Liebhard LLP https://www.bernlieb.com (212) 951-2030 [email protected]
	2025-11-03 07:20 4mo ago	2025-11-03 01:45 4mo ago	FLY-E GROUP, INC. (NASDAQ: FLYE) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Fly-E Group, Inc. Investors of Upcoming Deadline	stocknewsapi	FLYE
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Fly-E Group, Inc. (“Fly-E” or the “Company”) (NASDAQ: FLYE) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Fly-E Group, Inc. (NASDAQ: FLYE)?Did you purchase your shares between July 15, 2025 and August 14, 2025, inclusive?Did you lose money in your investment in Fly-E Group, Inc.? If you purchased or acquired Fly-E securities, and/or would like to discuss your legal rights and options please visit Fly-E Group, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected]. A lawsuit was filed in the United States District Court for the Eastern District of New York on behalf of investors who purchased or acquired the securities of Fly-E between July 15, 2025 and August 14, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers. According to the lawsuit, Defendants made misrepresentations concerning the safety of Fly-E’s lithium battery. If you wish to serve as lead plaintiff for the Class, you must file papers by November 7, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years. ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information: Peter Allocco Investor Relations Manager Bernstein Liebhard LLP https://www.bernlieb.com (212) 951-2030 [email protected]
	2025-11-03 07:20 4mo ago	2025-11-03 01:45 4mo ago	V.F. CORPORATION (NYSE: VFC) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds V.F. Corporation Investors of Upcoming Deadline	stocknewsapi	VFC
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds V.F. Corporation (“VFC” or the “Company”) (NYSE: VFC) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of V.F. Corporation (NYSE: VFC)?Did you purchase your shares between October 30, 2023 and May 20, 2025, inclusive?Did you lose money in your investment in V.F. Corporation? If you purchased or acquired VFC securities, and/or would like to discuss your legal rights and options please visit V.F. Corporation Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected]. A lawsuit was filed in the United States District Court for the District of Colorado on behalf of investors who purchased or acquired the securities of VFC between October 30, 2023 and May 20, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers. According to the lawsuit, Defendants made misrepresentations concerning VFC’s business plans. If you wish to serve as lead plaintiff for the Class, you must file papers by November 12, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years. ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information: Peter Allocco Investor Relations Manager Bernstein Liebhard LLP https://www.bernlieb.com (212) 951-2030 [email protected]
	2025-11-03 07:20 4mo ago	2025-11-03 01:45 4mo ago	FLUOR CORPORATION (NYSE: FLR) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Fluor Corporation Investors of Upcoming Deadline	stocknewsapi	FLR
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Fluor Corporation (“Fluor” or the “Company”) (NYSE: FLR) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Fluor Corporation (NYSE: FLR)?Did you purchase your shares between February 18, 2025 and July 31, 2025, inclusive?Did you lose money in your investment in Fluor Corporation? If you purchased or acquired Fluor securities, and/or would like to discuss your legal rights and options please visit Fluor Corporation Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected]. A lawsuit was filed in the United States District Court for the Northern District of Texas on behalf of investors who purchased or acquired the securities of Fluor between February 18, 2025 and July 31, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers. According to the lawsuit, Defendants made misrepresentations concerning the effectiveness of the Company’s risk mitigation strategy and the impact of economic uncertainty on Fluor’s business and financial results. If you wish to serve as lead plaintiff for the Class, you must file papers by November 14, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years. ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information: Peter Allocco Investor Relations Manager Bernstein Liebhard LLP https://www.bernlieb.com (212) 951-2030 [email protected]
	2025-11-03 07:20 4mo ago	2025-11-03 01:45 4mo ago	LANTHEUS HOLDINGS, INC. (NASDAQ: LNTH) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Lantheus Holdings, Inc. Investors of Upcoming Deadline	stocknewsapi	LNTH
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)?Did you purchase your shares between February 26, 2025 and August 5, 2025, inclusive?Did you lose money in your investment in Lantheus Holdings, Inc.? If you purchased or acquired Lantheus securities, and/or would like to discuss your legal rights and options please visit Lantheus Holdings, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected]. A lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired the securities of Lantheus between February 26, 2025 and August 5, 2025, inclusive. According to the lawsuit, Defendants made misrepresentations concerning the competitive position of the Company’s key Radiopharmaceutical Oncology product, Pylarify. If you wish to serve as lead plaintiff for the Class, you must file papers by November 10, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years. ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information: Peter Allocco Investor Relations Manager Bernstein Liebhard LLP https://www.bernlieb.com (212) 951-2030 [email protected]
	2025-11-03 07:20 4mo ago	2025-11-03 01:56 4mo ago	Ryanair Posts Net Profit Increase, Lifts Full-Year Passenger Outlook	stocknewsapi	RYAAY
The budget airline said earlier-than-expected deliveries of Boeing aircraft would allow it to carry more passengers in fiscal 2026 than previously forecast.
	2025-11-03 07:20 4mo ago	2025-11-03 01:59 4mo ago	Europe Seeking Greater AI Sovereignty, Accenture Report Finds	stocknewsapi	ACN
Balanced approach to AI sovereignty needed to ensure Europe’s competitiveness while protecting data MILAN--(BUSINESS WIRE)--A new study by Accenture (NYSE: ACN) has found that European organizations are placing greater emphasis on maintaining control over data and infrastructure which is likely to accelerate the demand for sovereign AI. Sovereign AI refers to the ability of a country to develop and deploy AI using local infrastructure, data, models and talent to protect data from foreign access, bolster competitiveness, and decrease reliance on overseas technology providers. In Europe, 62% of organizations are seeking sovereign solutions in response to current geopolitical uncertainty, a concern that’s heightened among Danish (80%), Irish (72%), and German (72%) organizations. Sectors with regulatory requirements and sensitive data are most likely to lead sovereign AI adoption including banking (76%), public service (69%), and utilities (70%). This trend is expected to grow over the next two years, as 60% of European organizations plan to increase investments in sovereign AI technology especially those in Germany (73%), Italy (71%) and Switzerland (64%). Mauro Macchi, Accenture CEO for EMEA commented, "Europe is facing an AI paradox. Its leaders understand the need to accelerate AI adoption to spur innovation and drive growth. But at the same time, because most AI technologies originate from outside the region, it could also be seen as a risk. A sovereign AI approach can help resolve this challenge by enabling European organizations to protect critical operations without hampering innovation and competitiveness. It's with an innovative and thriving economy that we’ll be able to invest in strengthening our technology ecosystem, enabling local champions to grow and compete on the global stage." Balancing data control and access to global innovation The survey highlights that, on average, just one-third (36%) of AI initiatives and data within European organizations require a sovereign approach due to regulatory requirements or data sensitivity. Capital markets and public services are sectors where such measures apply to a higher share of data. European organizations are seeking a balance between data control and access to global innovation, with 65% acknowledging that they cannot remain competitive without non-European technology providers. 57% are considering using sovereign solutions from both European and non-European providers. For its part, Accenture is helping Telia Cygate gain an early lead helping Swedish organizations adopt scalable and secure AI services. Accenture is also working across the ecosystem in Europe, including with AI infrastructure providers like Amsterdam-based Nebius, to provide clients with a foundation for their own sovereign AI factories that enable them to meet data residency requirements. Nebius is an AI cloud platform engineered to support the full lifecycle of AI workloads, integrating custom hardware, proprietary software and energy-efficient data centers located across Europe and the Middle East. Mauro Capo, Digital Sovereignty lead for Accenture in EMEA said, "A sovereign AI approach is not about holding everything in one place. The goal is to make technology choices according to the degree of control organizations want to exercise over data, AI infrastructure and models, while benefiting from the scale, service breadth and pace of innovation that some non-European providers offer. These choices are decided by the use case and national priorities. Some cases need only local data residency, while others, in defense for instance, call for full sovereignty over the different AI components - local data, infrastructure and model, advanced encryption, or even air-gapped systems when necessary.” Reframing sovereignty, from risk management to competitive advantage Only 19% of organizations view sovereign AI as a competitive advantage, while 48% cite compliance requirements as their primary motivation for adopting sovereign solutions. Sovereign AI is still perceived as a technical issue within businesses, as only 16% of European companies have made AI sovereignty a CEO or board-level concern. However, there's a growing recognition of its strategic importance, with 73% of organizations calling for governments and institutions, such as the European Union, to play a key role in enhancing Europe's digital sovereignty, through regulations, subsidies, or public investments. Small and medium enterprises are also seen as critical in this pursuit, with 70% of organizations considering it as important to helping them access sovereign solutions. Accenture recommends four actions to maximize opportunities from sovereign AI: CEO Ownership: Sovereign AI must be a CEO-led priority, aligning AI strategy with enterprise risk, growth, and geopolitical realities for maximum impact. Reframe Sovereignty: Organizations should shift from viewing sovereignty as mere risk mitigation to leveraging it as a source of value creation and competitive advantage. Expand Your Ecosystem: Companies should build hybrid ecosystems that combine local trust with global innovation, tailoring sovereignty measures to where they matter most. Redefine Architecture: Firms need to architect AI across a multi-cloud continuum, embedding sovereignty into every layer - data, infrastructure, models, and applications - for resilience and adaptability. About the research This study combines quantitative, qualitative and policy research to examine how governments and enterprises are advancing sovereign AI and sovereign cloud. It is based on a global survey of 1,928 organizations across 28 countries and 18 industries conducted during Jul–Aug 2025. Respondents were senior technology and policy leaders - CIOs, CTOs, chief data, AI and risk officers - from both public and private sectors. About Accenture Accenture is a leading solutions and global professional services company that helps the world’s leading enterprises reinvent by building their digital core and unleashing the power of AI to create value at speed across the enterprise, bringing together the talent of our approximately 779,000 people, our proprietary assets and platforms, and deep ecosystem relationships. Our strategy is to be the reinvention partner of choice for our clients and to be the most AI-enabled, client-focused, great place to work in the world. Through our Reinvention Services we bring together our capabilities across strategy, consulting, technology, operations, Song and Industry X with our deep industry expertise to create and deliver solutions and services for our clients. Our purpose is to deliver on the promise of technology and human ingenuity, and we measure our success by the 360° value we create for all our stakeholders. Visit us at accenture.com. Copyright © 2025 Accenture. All rights reserved. Accenture and its logo are registered trademarks of Accenture.
	2025-11-03 07:20 4mo ago	2025-11-03 02:00 4mo ago	Scatec ASA: Fixed income investor meetings	stocknewsapi	STECF
November 03, 2025 02:00 ET \| Source: Scatec ASA Oslo, 3 November 2025: Scatec ASA ("Scatec") has mandated Arctic Securities, DNB Carnegie, Nordea and SB1 Markets to arrange a series of fixed income investor meetings commencing Tuesday, 4 November 2025. A NOK 1,250 million (expected) senior unsecured green bond issue with a 4.25-year maturity may follow, subject to inter alia market conditions. The net proceeds of the green bond issue shall be applied towards repayment of outstanding corporate debt and general corporate purposes as set out in the Green Financing Framework. For further information, please contact: Andreas Austrell, SVP IR [email protected] +47 974 38 686 About Scatec ASA: Scatec is a leading renewable energy solutions provider, accelerating access to reliable and affordable clean energy in emerging markets. As a long-term player, we develop, build, own, and operate renewable energy plants, with 6.2 GW in operation and under construction across five continents today. We are committed to grow our renewable energy capacity, delivered by our passionate employees and partners who are driven by a common vision of 'Improving our Future'. Scatec is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'SCATC'. To learn more, visit www.scatec.com or connect with us on LinkedIn. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
	2025-11-03 07:20 4mo ago	2025-11-03 02:00 4mo ago	Aegon announces changes to its Board of Directors	stocknewsapi	AEG
Schiphol, November 3, 2025 - Aegon announces today that David Herzog, who was appointed as a member of the Board of Directors (BoD) at Aegon’s 2025 Annual General Meeting of shareholders (AGM), will succeed William Connelly as Chairman of the BoD as of November 13, 2025. In line with previous announcements, Mr Connelly will retire as Chairman and member of the BoD on the same date. Aegon also announces today that it will propose to its 2026 AGM to appoint Leni Boeren as a new member of its BoD. Mrs Boeren has extensive experience in both the financial services industry and the wider corporate sector. Her most recent executive role was as CEO of Kempen Capital Management N.V. and as a member of the Executive Board of Van Lanschot Kempen N.V. Prior to this role, Mrs Boeren was CEO and Chair of the Management Board of Robeco Groep N.V., and a member of the Executive Committee at Euronext N.V. Mrs Boeren currently holds non-executive roles at Mollie, NIBC Bank, Ohpen and Air France-KLM. In addition, Mrs Boeren holds several advisory roles, including her membership of the Capital Market Committee of the Dutch Authority for Financial Markets. William Connelly commented: “I am delighted that the Board will propose Leni Boeren as its new member. Leni has a deep understanding of the financial services and corporate sectors, and extensive experience in transforming companies. She is well placed to contribute to Aegon’s Board and support the execution of the company’s strategy. I am also pleased to pass the chairmanship of the Board to David Herzog, whose wealth of leadership experience in insurance and asset management will be crucial to Aegon's continued success. Looking back on my tenure, it has been a privilege to contribute to Aegon’s transformation, which I am confident will continue under David’s capable leadership.” David Herzog said: “I look forward to taking on the role of Chairman and working with my fellow Board members to continue advancing Aegon’s strategy and delivering value to our stakeholders. I also look forward to collaborating closely with our CEO, Lard Friese, whose strong leadership has been pivotal in shaping Aegon’s direction. I would like to thank Bill Connelly for his outstanding leadership and dedication to Aegon during his tenure as Chairman. Bill’s vision and commitment have been instrumental in guiding Aegon through its transformation, and I am privileged to build on the strong foundation he has established.” Contacts About Aegon Aegon is an international financial services holding company. Aegon’s ambition is to build leading businesses that offer their customers investment, protection, and retirement solutions. Aegon’s portfolio of businesses includes fully owned businesses in the United States and United Kingdom, and a global asset manager. Aegon also creates value by combining its international expertise with strong local partners via insurance joint-ventures in Spain & Portugal, China, and Brazil, and via asset management partnerships in France and China. In addition, Aegon owns a Bermuda-based life insurer and generates value via a strategic shareholding in a market leading Dutch insurance and pensions company. Aegon’s purpose of helping people live their best lives runs through all its activities. As a leading global investor and employer, Aegon seeks to have a positive impact by addressing critical environmental and societal issues. Aegon is headquartered in Schiphol, the Netherlands, domiciled in Bermuda, and listed on Euronext Amsterdam and the New York Stock Exchange. More information can be found at aegon.com. Forward-looking statements The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, could, is confident, will, and similar expressions as they relate to Aegon. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. In addition, any statements that refer to sustainability, environmental and social targets, commitments, goals, efforts and expectations and other events or circumstances that are partially dependent on future events are forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation, and expressly disclaims any duty, to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially and adversely from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following: Changes in general economic and/or governmental conditions, particularly in Bermuda, the United States, the United Kingdom and in relation to Aegon’s shareholding in ASR Nederland N.V. and asset management business, the Netherlands;Civil unrest, (geo-) political tensions, military action or other instability in countries or geographic regions that affect our operations or that affect global markets;Changes in the performance of financial markets, including emerging markets, such as with regard to: The frequency and severity of defaults by issuers in Aegon’s fixed income investment portfolios; The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of government exposure that Aegon holds;The impact from volatility in credit, equity, and interest rates; Changes in the performance of Aegon’s investment portfolio and decline in ratings of Aegon’s counterparties;The effect of tariffs and potential trade wars on trading markets and on economic growth, globally and in the markets where Aegon operates.Lowering of one or more of Aegon’s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegon’s ability to raise capital and on its liquidity and financial condition;Lowering of one or more of insurer financial strength ratings of Aegon’s insurance subsidiaries and the adverse impact such action may have on the written premium, policy retention, profitability and liquidity of its insurance subsidiaries;The effect of applicable Bermuda solvency requirements, the European Union’s Solvency II requirements, and applicable equivalent solvency requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain and our ability to pay dividends;Changes in the European Commission’s or European regulator’s position on the equivalence of the supervisory regime for insurance and reinsurance undertakings in force in Bermuda;Changes affecting interest rate levels and low or rapidly changing interest rate levels;Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates;The effects of global inflation, or inflation in the markets where Aegon operates;Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness;Increasing levels of competition, particularly in the United States, the United Kingdom, emerging markets and in relation to Aegon’s shareholding in ASR Nederland N.V. and asset management business, the Netherlands;Catastrophic events, either manmade or by nature, including by way of example acts of God, acts of terrorism, acts of war and pandemics, could result in material losses and significantly interrupt Aegon’s business;The frequency and severity of insured loss events;Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of Aegon’s insurance products and management of derivatives;Aegon’s projected results are highly sensitive to complex mathematical models of financial markets, mortality, longevity, and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect, or should errors in those models escape the controls in place to detect them, future performance will vary from projected results;Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations;Changes in customer behavior and public opinion in general related to, among other things, the type of products Aegon sells, including legal, regulatory or commercial necessity to meet changing customer expectations;Customer responsiveness to both new products and distribution channels;Third-party information used by us may prove to be inaccurate and change over time as methodologies and data availability and quality continue to evolve impacting our results and disclosures;As Aegon’s operations support complex transactions and are highly dependent on the proper functioning of information technology, operational risks such as system disruptions or failures, security or data privacy breaches, cyberattacks, human error, failure to safeguard personally identifiable information, changes in operational practices or inadequate controls including with respect to third parties with which Aegon does business, may disrupt Aegon’s business, damage its reputation and adversely affect its results of operations, financial condition and cash flows;Aegon’s failure to swiftly, effectively, and securely adapt and integrate emerging technologies;The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegon’s ability to complete, or obtain regulatory approval for, acquisitions and divestitures, integrate acquisitions, and realize anticipated results from such transactions, and its ability to separate businesses as part of divestitures. In particular, there is no certainty that Aegon’s review on a potential relocation of the company’s legal domicile and head office to the United States will result in a decision to pursue such a relocation. Furthermore, there is no guarantee, if pursued, what the manner, timing, and potential impacts of a relocation would be and if such relocation can be completed successfully.Aegon’s failure to achieve anticipated levels of earnings or operational efficiencies, as well as other management initiatives related to cost savings, Cash Capital at Holding, gross financial leverage and free cash flow;Changes in the policies of central banks and/or governments;Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business;Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for Aegon’s products;Consequences of an actual or potential break-up of the European Monetary Union in whole or in part, or further consequences of the exit of the United Kingdom from the European Union and potential consequences if other European Union countries leave the European Union;Changes in laws and regulations, or the interpretation thereof by regulators and courts, including as a result of comprehensive reform or shifts away from multilateral approaches to regulation of global or national operations, particularly regarding those laws and regulations related to ESG matters, those affecting Aegon’s operations’ ability to hire and retain key personnel, taxation of Aegon companies, the products Aegon sells, the attractiveness of certain products to its consumers and Aegon’s intellectual property;Regulatory changes relating to the pensions, investment, insurance industries and enforcing adjustments in the jurisdictions in which Aegon operates;Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU), national (such as Bermuda) or US federal or state level financial regulation or the application thereof to Aegon;Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily or otherwise, which may affect Aegon’s reported results, shareholders’ equity or regulatory capital adequacy levels;The rapidly changing landscape for ESG responsibilities, leading to potential challenges by private parties and governmental authorities, and/or changes in ESG standards and requirements, including assumptions, methodology and materiality, or a change by Aegon in applying such standards and requirements, voluntarily or otherwise, may affect Aegon’s ability to meet evolving standards and requirements, or Aegon’s ability to meet its sustainability and ESG-related goals, or related public expectations, which may also negatively affect Aegon’s reputation or the reputation of its board of directors or its management; Unexpected delays, difficulties, and expenses in executing against Aegon’s environmental, climate, or other ESG targets, goals and commitments, and changes in laws or regulations affecting us, such as changes in data privacy, environmental, health and safety laws; andReliance on third-party information in certain of Aegon’s disclosures, which may change over time as methodologies and data availability and quality continue to evolve. These factors, as well as any inaccuracies in third-party information used by Aegon, including in estimates or assumptions, may cause results to differ materially and adversely from statements, estimates, and beliefs made by Aegon or third-parties. Moreover, Aegon’s disclosures based on any standards may change due to revisions in framework requirements, availability of information, changes in its business or applicable governmental policies, or other factors, some of which may be beyond Aegon’s control. Additionally, Aegon's discussion of various ESG and other sustainability issues in this document or in other locations, including on our corporate website, may be informed by the interests of various stakeholders, as well as various ESG standards, frameworks, and regulations (including for the measurement and assessment of underlying data). As such, our disclosures on such issues, including climate-related disclosures, may include information that is not necessarily "material" under US securities laws for SEC reporting purposes, even if we use words such as "material" or "materiality" in relation to those statements. ESG expectations continue to evolve, often quickly, including for matters outside of our control; our disclosures are inherently dependent on the methodology (including any related assumptions or estimates) and data used, and there can be no guarantee that such disclosures will necessarily reflect or be consistent with the preferred practices or interpretations of particular stakeholders, either currently or in future. This document contains information that qualifies, or may qualify, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (596/2014). Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the 2024 Integrated Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. 20251103_PR_Aegon announces changes to its Board of Directors
	2025-11-03 07:20 4mo ago	2025-11-03 02:00 4mo ago	Guardian Metal Resources PLC Announces Board Changes	stocknewsapi	GMTLF
Mr. Michael X. Schlumpberger appointment to the Board LONDON, GB / ACCESS Newswire / November 3, 2025 / Guardian Metal Resources plc (LON:GMET)(OTCQB:GMTLF), a strategic mineral exploration and development company focused on tungsten in Nevada, U.S., is pleased to announce that Mr.
	2025-11-03 07:20 4mo ago	2025-11-03 02:00 4mo ago	Kosmos Energy Announces Third Quarter 2025 Results	stocknewsapi	KOS
DALLAS--(BUSINESS WIRE)--Kosmos Energy Ltd. (“Kosmos” or the “Company”) (NYSE/LSE: KOS) announced today its financial and operating results for the third quarter of 2025. For the quarter, the Company generated a net loss of $124 million, or $0.26 per diluted share. When adjusted for certain items that impact the comparability of results, the Company generated an adjusted net loss(1) of $72 million, or $0.15 per diluted share for the third quarter of 2025. THIRD QUARTER 2025 HIGHLIGHTS Net Production(2): ~65,500 barrels of oil equivalent per day (boepd), up 3% versus second quarter 2025, with sales of ~59,900 boepd Revenues: $311 million, or $56.39 per boe (excluding the impact of derivative cash settlements) Production expense: $148 million ($19.51 per boe excluding $59.4 million of production expenses associated with the Greater Tortue Ahmeyim (GTA) liquefied natural gas (LNG) project), down 39% versus second quarter 2025 Capital expenditures: $67 million Entered into a senior secured term loan with Shell for up to $250 million; funding of the first tranche of $150 million was completed post quarter-end with proceeds used to partially redeem the 2026 unsecured notes Completed the semi-annual re-determination of the reserve-based lending (“RBL”) facility, maintaining a borrowing base in excess of the RBL’s $1.35 billion facility size During the third quarter, 6.8 gross LNG cargos were lifted from the GTA project offshore Mauritania and Senegal First producer well of the 2025/26 Jubilee drilling campaign brought online with ~10,000 bopd average contribution Commenting on the Company’s third quarter 2025 performance, Chairman and Chief Executive Officer Andrew G. Inglis said: "We set out this year with three clear priorities: Increase production, reduce costs and enhance the resilience of the balance sheet. During the period, we have continued to make good progress against each of these priorities. On production, GTA is fully operational, with ~7 gross LNG cargos lifted during the quarter, and further upside to be tested in the fourth quarter. With the second Jubilee producer well now being drilled and due online around year end, and the drilling program continuing into 2026, we expect company production to continue to rise through next year. On costs, we now expect capital expenditure to be below $350 million in 2025, more than 60% lower year-on-year. Operating costs across every business were lower quarter over quarter and we continue to work to further reduce operating costs across the portfolio, particularly on GTA into 2026. In addition, we remain on track to deliver the targeted $25 million of overhead reduction by year-end. On the balance sheet, we raised additional liquidity with the Shell term loan, which is being used to repay our 2026 maturities. We also completed the semi-annual re-determination of our RBL facility and have added more hedges for 2026. As we navigate through near-term volatility, our priorities for Kosmos remain consistent: long term value creation through growing production, reducing costs and maximizing cash flow to accelerate debt repayment and reduce leverage.” FINANCIAL UPDATE Kosmos entered into a senior secured term loan facility (the “Term Facility”) with Shell Trading (US) Company (“Shell”) for up to $250 million, using $150 million to partially redeem the outstanding 2026 unsecured notes in early October. The remaining $100 million of outstanding 2026 notes is planned to be repaid in advance of the maturity date from the undrawn portion of the Term Facility in the first quarter of 2026. The Company also continues to evaluate raising additional secured debt capital to proactively manage upcoming maturities. During the third quarter, Kosmos completed the semi-annual re-determination of its RBL facility with a borrowing base in excess of the $1.35 billion facility size. In addition, the Company completed the liquidity test covering the 2027 unsecured notes, which was carried out alongside the RBL re-determination. Kosmos has continued to add more hedges as part of a rolling hedging program to provide downside protection against a volatile commodity price backdrop. The company now has 2.5 million barrels of remaining 2025 oil production hedged with an average floor of approximately $62/barrel. Kosmos took advantage of periods of higher oil prices during the third quarter to add more hedges for the 2026 hedging program. Kosmos now has 8.5 million barrels of oil hedged for 2026 with an average floor of $66/barrel, weighted towards the first half of the year and is targeting around 50% of 2026 oil production to be hedged by year-end. Net capital expenditure for the third quarter of 2025 was $67 million, below guidance due to lower spend in Ghana and the Gulf of America. We now expect full year capital expenditures to be lower than $350 million. The Company remains on track to deliver the targeted $25 million overhead reduction by year-end. The Company generated net cash used in operating activities of approximately $(28) million and free cash flow(1) of approximately $(99) million during the quarter. Excluding the working capital draw communicated with the second quarter results in August, which largely related to final accrued capital expenditure on Phase 1 of the GTA project, free cash flow was broadly neutral for the third quarter. Kosmos exited the third quarter of 2025 with approximately $2.9 billion of net debt(1) and liquidity of approximately $540 million(3). OPERATIONAL UPDATE Production Total net production(2) in the third quarter of 2025 averaged approximately 65,500 boepd with the quarter-on-quarter increase largely driven by the ramp up at GTA and increased production at Jubilee. The Company exited the quarter in a net underlift position of approximately 0.6 mmboe. Mauritania and Senegal GTA Phase 1 production continued to ramp up during the quarter averaging approximately 11,400 boepd net. During the quarter, 6.8 gross LNG cargos were lifted, in line with guidance. Post quarter-end, an additional 2.7 gross LNG cargos were lifted (bringing the total through October to 13.5), along with the first gross condensate cargo. Lowering operating costs for GTA Phase 1 remains a priority for the partnership. Net operating costs on the project decreased approximately $10 million quarter-on-quarter, with additional actions to further reduce costs ongoing, including the FPSO lease re-financing which is targeted for completion by year-end, and the implementation of a lower-cost operating model. During the third quarter, planned startup maintenance was carried out on three of the four FLNG trains. All three trains are back online and the fourth train is scheduled to undergo one week of similar maintenance in the fourth quarter. With Phase 1 targeting nameplate production at the end of the fourth quarter, the partnership is now focusing on future expansion through Phase 1+, a low-cost brownfield expansion. This is expected to approximately double gas throughput by 2029, leveraging the existing infrastructure in place. Ghana Production in Ghana averaged approximately 31,300 boepd net in the third quarter of 2025. Kosmos lifted 2 cargos from Ghana during the quarter, as expected. At Jubilee (38.6% working interest), oil production in the third quarter averaged approximately 62,500 bopd gross. The first producer well of the 2025/26 Jubilee drilling campaign came online in July and initial production levels have been encouraging, averaging ~10,000 boepd through the first three months. Following a period of scheduled maintenance, the Noble Venturer rig arrived back in field in mid-October and has spud the second planned producer well, which is expected online around year end. Within the original 2026 drilling campaign budget, the joint venture partners have approved the activity set, which now includes the 4 planned producers and an additional water injector. In the third quarter of 2025, Ghana gas production net to Kosmos was approximately 5,200 boepd, lower than planned as a result of extended scheduled maintenance on the onshore gas processing plant. At TEN (20.4% working interest), oil production averaged approximately 16,100 bopd gross for the third quarter. The TEN partnership is finalizing a sale and purchase agreement to acquire the TEN FPSO at the end of its current lease, planned to be signed by year-end. We expect this to significantly reduce TEN operating costs and positively impact our leverage in 2025 and beyond. Post the signing of the Memorandum of Understanding (MoU) with the Government of Ghana last quarter, all documentation for the extension of the production licenses to 2040 have been prepared for submission to the government for final approval. Once approved, Kosmos expects to recognize a material uplift in its 2P reserve base. Gulf of America Production in the Gulf of America averaged approximately 16,600 boepd net (~84% oil) during the third quarter, in line with guidance helped by strong performance from Odd Job and Kodiak and no storm downtime, offset by some unplanned facility downtime and the Winterfell-4 well. The Winterfell-4 well was abandoned in September by the operator due to challenges encountered during completion operations arising from the collapse of the production casing. As a result, all associated drilling and completion costs of approximately $51.1 million related to Winterfell-4 have been written off in the third quarter of 2025. The partnership is reviewing alternative options to access the reserves targeted by Winterfell-4. In 2026, our focus will be on restoring production from the Winterfell-3 fault block. On Tiberius, Kosmos (operator, 50% working interest) continues to progress the development plan with our partner Oxy (50% working interest). A production handling agreement for the Oxy-operated Lucius platform was executed in the third quarter. Final investment decision and a farm down to reduce Kosmos’ working interest is expected in 2026. On Gettysburg, a discovered resource opportunity acquired in a previous lease sale, Kosmos (25% working interest) has partnered with Shell (operator, 75% working interest), to plan and progress a low-cost, single well tie-back development to Shell’s operated-Appomattox facility. Equatorial Guinea Production in Equatorial Guinea averaged approximately 17,700 bopd gross and 6,200 bopd net in the third quarter. Kosmos lifted 0.7 cargos from Equatorial Guinea during the quarter in line with guidance. As previously communicated, third quarter production was impacted by subsea pump mechanical failures at Ceiba. The first pump was repaired ahead of schedule early in the fourth quarter, and the second pump is now also expected online in the fourth quarter followed by the third pump in first quarter of 2026. (1) A Non-GAAP measure, see attached reconciliation of non-GAAP measure. (2) Production means net entitlement volumes. In Ghana, Equatorial Guinea, and Mauritania and Senegal this means those volumes net to Kosmos' working interest or participating interest and net of royalty or production sharing contract effect. In the Gulf of America, this means those volumes net to Kosmos' working interest and net of royalty. (3) At September 30, 2025, we had liquidity of approximately $540 million consisting of approximately $64 million in cash and cash equivalents, undrawn availability under the Facility of $225 million and undrawn availability under the Term Facility of $250 million. Under the terms of the Credit Agreement, borrowings on the Term Facility are required to be utilized to pay down the 7.125% Senior Notes due 2026 unless otherwise previously repaid. Conference Call and Webcast Information Kosmos will host a conference call and webcast to discuss third quarter 2025 financial and operating results today, November 3, 2025, at 10:00 a.m. Central time (11:00 a.m. Eastern time). The live webcast of the event can be accessed on the Investors page of Kosmos’ website at http://investors.kosmosenergy.com/investor-events. The dial-in telephone number for the call is +1-877-407-0784. Callers in the United Kingdom should call 0800 756 3429. Callers outside the United States should dial +1-201-689-8560. A replay of the webcast will be available on the Investors page of Kosmos’ website for approximately 90 days following the event. About Kosmos Energy Kosmos Energy is a leading deepwater exploration and production company focused on meeting the world’s growing demand for energy. We have diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. Additionally, in the proven basins where we operate we are advancing high-quality development opportunities, which have come from our exploration success. Kosmos is listed on the NYSE and LSE and is traded under the ticker symbol KOS. As an ethical and transparent company, Kosmos is committed to doing things the right way. The Company’s Business Principles articulate our commitment to transparency, ethics, human rights, safety and the environment. Read more about this commitment in the Kosmos Sustainability Report. For additional information, visit www.kosmosenergy.com. Non-GAAP Financial Measures EBITDAX, Adjusted net income (loss), Adjusted net income (loss) per share, free cash flow, and net debt are supplemental non-GAAP financial measures used by management and external users of the Company's consolidated financial statements, such as industry analysts, investors, lenders and rating agencies. The Company defines EBITDAX as Net income (loss) plus (i) exploration expense, (ii) depletion, depreciation and amortization expense, (iii) equity based compensation expense, (iv) unrealized (gain) loss on commodity derivatives (realized losses are deducted and realized gains are added back), (v) (gain) loss on sale of oil and gas properties, (vi) interest (income) expense, (vii) income taxes, (viii) debt modifications and extinguishments, (ix) doubtful accounts expense and (x) similar other material items which management believes affect the comparability of operating results. The Company defines Adjusted net income (loss) as Net income (loss) adjusted for certain items that impact the comparability of results. The Company defines free cash flow as net cash provided by operating activities less Oil and gas assets, Other property, and certain other items that may affect the comparability of results and excludes non-recurring activity such as acquisitions, divestitures and National Oil Company ("NOC") financing. NOC financing refers to the amounts funded by Kosmos under the Carry Advance Agreements that the Company has in place with the national oil companies of each of Mauritania and Senegal related to the financing of the respective national oil companies’ share of certain development costs at Greater Tortue Ahmeyim. The Company defines net debt as total long-term debt less cash and cash equivalents and total restricted cash. We believe that EBITDAX, Adjusted net income (loss), Adjusted net income (loss) per share, free cash flow, Net debt and other similar measures are useful to investors because they are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in the oil and gas sector and will provide investors with a useful tool for assessing the comparability between periods, among securities analysts, as well as company by company. EBITDAX, Adjusted net income (loss), Adjusted net income (loss) per share, free cash flow, and net debt as presented by us may not be comparable to similarly titled measures of other companies. This release also contains certain forward-looking non-GAAP financial measures, including free cash flow. Due to the forward-looking nature of the aforementioned non-GAAP financial measures, management cannot reliably or reasonably predict certain of the necessary components of the most directly comparable forward-looking GAAP measures, such as future impairments and future changes in working capital. Accordingly, we are unable to present a quantitative reconciliation of such forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures. Amounts excluded from these non-GAAP measures in future periods could be significant. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that Kosmos expects, believes or anticipates will or may occur in the future are forward-looking statements. Kosmos’ estimates and forward-looking statements are mainly based on its current expectations and estimates of future events and trends, which affect or may affect its businesses and operations. Although Kosmos believes that these estimates and forward-looking statements are based upon reasonable assumptions, they are subject to several risks and uncertainties and are made in light of information currently available to Kosmos. When used in this press release, the words “anticipate,” “believe,” “intend,” “expect,” “plan,” “will” or other similar words are intended to identify forward-looking statements. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Kosmos, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. Further information on such assumptions, risks and uncertainties is available in Kosmos’ Securities and Exchange Commission (“SEC”) filings. Kosmos undertakes no obligation and does not intend to update or correct these forward-looking statements to reflect events or circumstances occurring after the date of this press release, except as required by applicable law. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement. Kosmos Energy Ltd. Consolidated Statements of Operations (In thousands, except per share amounts, unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Revenues and other income: Oil and gas revenue $ 310,959 $ 407,794 $ 993,729 $ 1,277,797 Gain on sale of assets — — 600 — Other income, net 270 37 849 109 Total revenues and other income 311,229 407,831 995,178 1,277,906 Costs and expenses: Oil and gas production 147,696 133,471 558,122 377,822 Exploration expenses 54,948 14,697 68,686 39,992 General and administrative 12,886 23,298 58,215 76,724 Depletion, depreciation and amortization 141,514 120,728 413,449 311,750 Interest and other financing costs, net 57,919 22,112 164,595 75,839 Derivatives, net (3,646 ) (15,254 ) (18,480 ) 5,716 Other expenses, net 6,384 2,227 14,854 6,418 Total costs and expenses 417,701 301,279 1,259,441 894,261 Income (loss) before income taxes (106,472 ) 106,552 (264,263 ) 383,645 Income tax expense 17,827 61,578 58,382 187,215 Net income (loss) $ (124,299 ) $ 44,974 $ (322,645 ) $ 196,430 Net income (loss) per share: Basic $ (0.26 ) $ 0.10 $ (0.68 ) $ 0.42 Diluted $ (0.26 ) $ 0.09 $ (0.68 ) $ 0.41 Weighted average number of shares used to compute net income (loss) per share: Basic 478,254 471,816 477,344 470,491 Diluted 478,254 479,190 477,344 478,701 Kosmos Energy Ltd. Condensed Consolidated Balance Sheets (In thousands, unaudited) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 64,032 $ 84,972 Receivables, net 103,330 164,959 Other current assets 198,205 196,201 Total current assets 365,567 446,132 Property and equipment, net 4,208,535 4,444,221 Other non-current assets 515,639 418,635 Total assets $ 5,089,741 $ 5,308,988 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 200,809 $ 349,994 Accrued liabilities 251,310 244,954 Current maturities of long-term debt 250,000 — Other current liabilities 3,239 — Total current liabilities 705,358 594,948 Long-term liabilities: Long-term debt, net 2,728,500 2,744,712 Deferred tax liabilities 313,426 313,433 Other non-current liabilities 443,670 455,471 Total long-term liabilities 3,485,596 3,513,616 Total stockholders’ equity 898,787 1,200,424 Total liabilities and stockholders’ equity $ 5,089,741 $ 5,308,988 Kosmos Energy Ltd. Condensed Consolidated Statements of Cash Flow (In thousands, unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Operating activities: Net income (loss) $ (124,299 ) $ 44,974 $ (322,645 ) $ 196,430 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depletion, depreciation and amortization (including deferred financing costs) 143,403 122,887 419,111 318,564 Deferred income taxes (950 ) 6,081 686 11,280 Unsuccessful well costs and leasehold impairments 51,211 1,187 51,373 3,872 Change in fair value of derivatives (2,792 ) (9,298 ) (10,675 ) 11,808 Cash settlements on derivatives, net(1) (3,480 ) (7,388 ) 2,801 (14,754 ) Equity-based compensation 5,302 10,034 21,009 27,849 Gain on sale of assets — — (600 ) — Debt modifications and extinguishments — 2,263 — 24,794 Other (2,986 ) (138 ) (11,492 ) (12,126 ) Changes in assets and liabilities: Net changes in working capital (92,977 ) (164,320 ) (50,856 ) (65,215 ) Net cash provided by (used in) operating activities (27,568 ) 6,282 98,712 502,502 Investing activities Oil and gas assets (71,367 ) (219,245 ) (244,133 ) (772,238 ) Notes receivable and other investing activities — — (86,791 ) (2,575 ) Net cash used in investing activities (71,367 ) (219,245 ) (330,924 ) (774,813 ) Financing activities: Borrowings under long-term debt 175,000 100,000 375,000 275,000 Payments on long-term debt (50,000 ) — (150,000 ) (350,000 ) Net proceeds from issuance of senior notes — 494,855 — 885,285 Purchase of capped call transactions — — — (49,800 ) Repurchase of senior notes — (499,515 ) — (499,515 ) Other financing costs — (4,609 ) (1 ) (35,534 ) Net cash provided by financing activities 125,000 90,731 224,999 225,436 Net increase (decrease) in cash, cash equivalents and restricted cash 26,065 (122,232 ) (7,213 ) (46,875 ) Cash, cash equivalents and restricted cash at beginning of period 51,999 174,118 85,277 98,761 Cash, cash equivalents and restricted cash at end of period $ 78,064 $ 51,886 $ 78,064 $ 51,886 Kosmos Energy Ltd. EBITDAX (In thousands, unaudited) Three Months Ended Nine months ended Twelve Months Ended September 30, 2025 September 30, 2024 September 30, 2025 September 30, 2024 September 30, 2025 Net income (loss) $ (124,299 ) $ 44,974 $ (322,645 ) $ 196,430 $ (329,224 ) Exploration expenses 54,948 14,697 68,686 39,992 148,601 Depletion, depreciation and amortization 141,514 120,728 413,449 311,750 558,473 Equity-based compensation 5,302 10,034 21,009 27,849 31,111 Derivatives, net (3,646 ) (15,254 ) (18,480 ) 5,716 (12,097 ) Cash settlements on commodity derivatives (2,324 ) (2,532 ) 7,340 (9,956 ) 4,808 Other expenses, net(1) 6,384 2,227 14,854 6,418 26,139 Gain on sale of assets — — (600 ) — (600 ) Interest and other financing costs, net 57,919 22,112 164,595 75,839 177,354 Income tax expense 17,827 61,578 58,382 187,215 31,128 EBITDAX $ 153,625 $ 258,564 $ 406,590 $ 841,253 $ 635,693 EBITDAX - M/S (21,988 ) (42,986 ) (131,397 ) (66,418 ) (169,336 ) EBITDAX - Base Business $ 175,613 $ 301,550 $ 537,987 $ 907,671 $ 805,029 September 30, December 31, 2025 2024 Total long-term debt $ 3,025,274 $ 2,800,274 Cash and cash equivalents 64,032 84,972 Total restricted cash 14,032 305 Net debt $ 2,947,210 $ 2,714,997 Kosmos Energy Ltd. Adjusted Net Income (Loss) (In thousands, except per share amounts, unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Net income (loss) $ (124,299 ) $ 44,974 $ (322,645 ) $ 196,430 Derivatives, net (3,646 ) (15,254 ) (18,480 ) 5,716 Cash settlements on commodity derivatives (2,324 ) (2,532 ) 7,340 (9,956 ) Gain on sale of assets — — (600 ) — Other, net(2) 6,358 1,965 14,386 5,892 Impairment of suspended well costs 51,060 — 51,060 — Debt modifications and extinguishments — 2,263 — 24,794 Total selected items before tax 51,448 (13,558 ) 53,706 26,446 Income tax (expense) benefit on adjustments(1) 575 6,186 (1,459 ) 2,269 Impact of valuation adjustments and other tax items — — — (7,963 ) Adjusted net income (loss) $ (72,276 ) 37,602 (270,398 ) 217,182 Net income (loss) per diluted share $ (0.26 ) $ 0.09 $ (0.68 ) $ 0.41 Derivatives, net (0.01 ) (0.03 ) (0.04 ) 0.01 Cash settlements on commodity derivatives — — 0.02 (0.01 ) Other, net(2) 0.01 — 0.03 0.01 Impairment of suspended well costs 0.11 — 0.10 — Debt modifications and extinguishments — — — 0.05 Total selected items before tax 0.11 (0.03 ) 0.11 0.06 Income tax (expense) benefit on adjustments(1) — 0.02 — Impact of valuation adjustments and other tax items — — — (0.02 ) Adjusted net income (loss) per diluted share $ (0.15 ) $ 0.08 $ (0.57 ) $ 0.45 Weighted average number of diluted shares 478,254 479,190 477,344 478,701 Kosmos Energy Ltd. Free Cash Flow (In thousands, unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Reconciliation of free cash flow: Net cash provided by (used in) operating activities $ (27,568 ) $ 6,282 $ 98,712 $ 502,502 Net cash used for oil and gas assets (71,367 ) (219,245 ) (244,133 ) (772,238 ) Free cash flow (98,935 ) (212,963 ) (145,421 ) (269,736 ) Net cash provided by (used in) operating activities - M/S (97,195 ) (56,484 ) (200,456 ) 42,542 Net cash used for oil and gas assets - M/S $ (7,744 ) $ (110,804 ) $ (71,321 ) $ (388,412 ) Base business free cash flow $ 6,004 $ (45,675 ) $ 126,356 $ 76,134 Kosmos Energy Ltd. Operational Summary (In thousands, except barrel and per barrel data, unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Net Volume Sold Oil (MMBbl) 3.799 5.135 12.822 15.234 Gas (MMcf) 9.712 (1) 3.554 (2) 21.004 (1) 11.991 (2) NGL (MMBbl) 0.097 0.084 0.301 0.232 Total (MMBoe) 5.515 5.811 16.624 17.465 Total (Mboepd) 59.942 63.167 60.893 63.739 Revenue Oil sales $ 255,661 $ 393,555 $ 880,584 $ 1,230,772 Gas sales 53,761 12,586 107,439 42,218 NGL sales 1,537 1,653 5,706 4,807 Total oil and gas revenue 310,959 407,794 993,729 1,277,797 Cash settlements on commodity derivatives (2,324 ) (2,532 ) 7,340 (9,956 ) Realized revenue $ 308,635 $ 405,262 $ 1,001,069 $ 1,267,841 Oil and Gas Production Costs $ 147,696 (1) $ 133,471 (2) $ 558,122 (1) $ 377,822 (2) Sales per Bbl/Mcf/Boe Average oil sales price per Bbl $ 67.30 $ 76.64 $ 68.68 $ 80.79 Average gas sales price per Mcf 5.54 3.54 5.12 3.52 Average NGL sales price per Bbl 15.85 19.68 18.96 20.72 Average total sales price per Boe 56.39 70.18 59.78 73.16 Cash settlements on commodity derivatives per Boe (0.42 ) (0.44 ) 0.44 (0.57 ) Realized revenue per Boe 55.97 69.74 60.22 72.59 Oil and gas production costs per Boe $ 26.78 $ 22.97 $ 33.57 $ 21.64 Oil and gas production costs per Boe ex. M/S (1)(2) $ 19.51 $ 16.14 $ 24.67 $ 18.32 _____________________________________ (1) Includes $59.4 million and $186.6 million for the three and nine months ended September 30, 2025, respectively, of oil and gas production costs related to the LNG production at the GTA Phase 1 project in Mauritania and Senegal. GTA Phase 1 project LNG sales volumes for the three and nine months ended September 30, 2025 were 5.932 MMcf and 9.376 MMcf, respectively. Oil and gas production costs per Boe excluding the GTA Phase 1 LNG project in Mauritania and Senegal for the three and nine months ended September 30, 2025, was $19.51 and $24.67, respectively. First LNG was achieved in February 2025 and the first LNG cargo was successfully completed in April 2025. (2) Includes $39.7 million and $57.9 million for the three and nine months ended September 30, 2024, respectively, of oil and gas production costs related to the LNG production at the GTA Phase 1 project in Mauritania and Senegal. First LNG was achieved in February 2025 and the first LNG cargo was successfully completed in April 2025. Oil and gas production costs per Boe excluding the GTA Phase 1 LNG project in Mauritania and Senegal for the three and nine months ended September 30, 2024, was $16.14 and $18.32, respectively. Kosmos was underlifted by approximately 0.6 million barrels of oil equivalent (mmboe) as of September 30, 2025. Kosmos Energy Ltd. Hedging Summary As of September 30, 2025(1) (Unaudited) Weighted Average Price per Bbl Index MBbl Floor(2) Sold Put Ceiling 2025: Two-way collars Dated Brent 2,000 $ 60.00 — $ 74.94 Three-way collars Dated Brent 500 70.00 55.00 85.00 2026: Two-way collars 1H26 Dated Brent 1,000 $ 60.00 — $ 74.75 Three-way collars FY26 Dated Brent 2,000 60.00 50.00 75.51 Swaps 1H26 Dated Brent 1,000 72.90 — — Swaps FY26 Dated Brent 3,000 70.62 — — Swaps FY26 WTI 1,500 64.83 — — _____________________________________ (1) Please see the Company’s filed 10-Q for additional disclosure on hedging material. Includes hedging position as of September 30, 2025 and hedges put in place through filing date. (2) “Floor” represents floor price for collars and strike price for purchased puts. Note: Excludes 2.0 MMBbls of Dated Brent sold calls with a strike price of $80.00 per Bbl and 2.0 MMBbls of Dated Brent sold puts with a strike price of $55.00 in 2026. Excludes 1.5 MMBbls of WTI sold puts with a strike price of $50.00 in 2026. 2025 Guidance 4Q 2025 FY 2025 Guidance Production(1,2,3) 66,000 - 72,000 boe per day ~65,000 boe per day Opex(4) $15.00 - $18.00 per boe ~$22.00 per boe DD&A $21.00 - $23.00 per boe $22.00 - $24.00 per boe G&A(~66% cash) ~$15 million ~$75 million Exploration Expense(5) ~$10 million $25 - $45 million Net Interest Expense(6) $55 - $60 million ~$220 million Tax $4.00 - $6.00 per boe $4.00 - $6.00 per boe Capital Expenditure $80 - $100 million <$350 million _____________________________________ Note: Ghana / Equatorial Guinea / Mauritania & Senegal revenue calculated by number of cargos. (1) 4Q 2025 net cargo forecast – Ghana: 2-3 cargos / Equatorial Guinea: 0.5 cargo. FY 2025 Ghana: 9-10 cargos / Equatorial Guinea 2.7 cargos. Average cargo sizes 950,000 barrels of oil. (2) 4Q 2025 gross cargo forecast - Mauritania & Senegal: 7-8.5 cargos. FY 2025: 18-19 cargos. Average cargo size ~170,000 m3 with Kosmos NRI of ~24%. (3) Gulf of America Production: 4Q 2025 forecast 17,000 - 19,000 boe per day. FY 2025: 17,000-19,000 boe per day. Oil/Gas/NGL split for 2025: ~83%/~11%/~6%. (4) FY 2025 opex excludes operating costs associated with GTA, which are expected to total approximately $225 - $245 million net ($45 - $55 million in 4Q 2025). These values include cost associated with the FPSO lease which total approximately $60 million FY 2025 and $15 million 4Q 2025. (5) Excludes leasehold impairments and dry hole costs (6) Includes capitalized interest More News From Kosmos Energy Ltd.
	2025-11-03 07:20 4mo ago	2025-11-03 02:00 4mo ago	Notice to holders of Icelandic Depository Receipts Confirmation of Effective Date for Conversion of Icelandic Depository Receipts (IDRs) into Depositary Interests (DIs)	stocknewsapi	AMRQF
November 03, 2025 02:00 ET \| Source: Amaroq Ltd. Reykjavík, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amaroq Ltd. (“Amaroq” or the “Company”) Notice to holders of Icelandic Depository Receipts Confirmation of Effective Date for Conversion of Icelandic Depository Receipts (IDRs) into Depositary Interests (DIs) TORONTO, ONTARIO – 03 November 2025 – Amaroq Ltd. (AIM, TSX-V, NASDAQ Iceland: AMRQ, OTCQX: AMRQF), an independent mine development corporation focused on unlocking Greenland’s mineral potential, further to the Company’s announcement dated October 21, 2025 regarding the simplification and streamlining of Amaroq’s securities under a single ISIN, hereby confirms the effective date for the automatic conversion of Icelandic Depository Receipts (“IDRs”) (ISIN IS0000034569) into Depositary Interests (“DIs”) (ISIN CA02311U1030): Effective Date: November 11, 2025 On the Effective Date: IDRs issued by Arion Banki hf. will be removed from investor accounts in Iceland; and an equivalent number of DIs (ISIN CA02311U1030) will be automatically credited to the same accounts. Trading of Amaroq DIs on Nasdaq Iceland will commence under the ISIN CA02311U1030 and ticker symbol AMRQ, denominated in Icelandic króna (ISK). The conversion will occur automatically, and no action is required from shareholders. As Depositary Interests replicate direct shareholding, the change is a technical adjustment only, with no impact on underlying shares or investor rights. Temporary Suspension of Cross-Border Conversions To facilitate the technical completion of this process, cross-border conversions between the Canadian and Icelandic markets will be temporarily suspended on 5 November - 5 business days prior to the effective date. During this period, no new transfers or conversions of shares between the two markets will be processed. Normal cross-border conversion functionality will resume immediately following completion of the conversion on the effective date. For technical information or to prepare internal procedures ahead of the conversion, custodians may contact Nasdaq CSD Iceland at [email protected]. Enquiries: Amaroq Ltd. c/o Ed Westropp, Head of BD and Corporate Affairs +44 (0)7385755711 [email protected] Eddie Wyvill, Corporate Development +44 (0)7713 126727 [email protected] Panmure Liberum Limited (Nominated Adviser and Corporate Broker) Scott Mathieson Freddie Wooding +44 (0) 20 7886 2500 Canaccord Genuity Limited (Corporate Broker) James Asensio Harry Rees Tel: +44 (0) 20 7523 8000 Camarco (Financial PR) Billy Clegg Elfie Kent Fergus Young +44 (0) 20 3757 4980 [email protected] For Company updates: Follow @Amaroq Ltd. on X (Formerly known as Twitter) Follow Amaroq Ltd. on LinkedIn Further Information: About Amaroq Amaroq’s principal business objectives are the identification, acquisition, exploration, and development of gold and strategic metal properties in South Greenland. The Company’s principal asset is a 100% interest in the Nalunaq Gold mine. The Company has a portfolio of gold and strategic metal assets in Southern Greenland covering the two known gold belts in the region as well as advanced exploration projects at Stendalen and the Sava Copper Belt exploring for Strategic metals such as Copper, Nickel, Rare Earths and other minerals. Amaroq is continued under the Business Corporations Act (Ontario) and wholly owns Nalunaq A/S, incorporated under the Greenland Companies Act. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Inside Information This announcement does not contain inside information.
	2025-11-03 07:20 4mo ago	2025-11-03 02:03 4mo ago	Eni, Petronas form joint venture to combine oil and gas assets	stocknewsapi	E
By Reuters November 3, 20257:06 AM UTCUpdated ago Item 1 of 2 The logo of Italian energy company Eni is seen at a gas station in Rome, Italy September 30, 2018. REUTERS/Alessandro Bianchi [1/2]The logo of Italian energy company Eni is seen at a gas station in Rome, Italy September 30, 2018. REUTERS/Alessandro Bianchi Purchase Licensing Rights, opens new tab CompaniesDUBAI, Nov 3 (Reuters) - Italy's Eni and Malaysia's state energy firm Petronas said on Monday they had signed a binding agreement to form a jointly owned company combining their upstream oil and gas assets in Indonesia and Malaysia. The new entity, NewCo, will manage 19 assets, 14 in Indonesia and five in Malaysia, with plans to invest over $15 billion in the next five years to develop about 3 billion barrels of discovered reserves and explore a further 10 billion barrels. Sign up here. The agreement was signed at ADIPEC in Abu Dhabi. Reporting by Yousef Saba; Writing by Tala Ramadan; Editing by Kim Coghill Our Standards: The Thomson Reuters Trust Principles., opens new tab
	2025-11-03 07:20 4mo ago	2025-11-03 02:08 4mo ago	Coursera: Thesis On Track, Buying On Dip	stocknewsapi	COUR
Analyst’s Disclosure:I/we have a beneficial long position in the shares of COUR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
	2025-11-03 07:20 4mo ago	2025-11-03 02:09 4mo ago	BP to sell stakes in US onshore midstream assets for $1.5 billion	stocknewsapi	BP
By Reuters November 3, 20257:16 AM UTCUpdated ago The BP logo is seen at a BP gas station in Manhattan, New York City, U.S., November 24, 2021. REUTERS/Andrew Kelly Purchase Licensing Rights, opens new tab CompaniesNov 3 (Reuters) - BP (BP.L), opens new tab said on Monday it would sell stakes in the Permian and Eagle Ford midstream assets of its U.S. onshore oil and gas business for $1.5 billion to funds managed by investment firm Sixth Street. The sale comes as BP reviews how to develop its oil and gas production assets and cut costs as part of a $20 billion divestment programme by end-2027. Sign up here. It has been under pressure from investors after years of underperforming rivals and also the target of activist investor Elliott. BP's U.S. onshore oil and gas business, bpx energy, will hold a 51% stake in the Permian assets and 25% in the Eagle Ford assets after the deal, the oil major said. Reporting by Shashwat Awasthi in Bengaluru; Editing by Subhranshu Sahu Our Standards: The Thomson Reuters Trust Principles., opens new tab
	2025-11-03 07:20 4mo ago	2025-11-03 02:12 4mo ago	FLYE Investors Have Opportunity to Lead Fly-E Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm	stocknewsapi	FLYE
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fly-E Group, Inc. ("Fly-E" or "the Company") (NASDAQ: FLYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 15, 2025, and August 14, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before November 7, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Fly-E shared optimistic revenue goals with investors only for its actual performance to fall far short of its projections. The Company overstated its brand reputation, cost reductions, and ability to secure favorable pricing from suppliers. The Company failed to successfully grow its sales network. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Fly-E, investors suffered damages. Join the case to recover your losses The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq., www.schallfirm.com Office: 310-301-3335 [email protected] SOURCE The Schall Law Firm
	2025-11-03 07:20 4mo ago	2025-11-03 02:12 4mo ago	Tronox Holdings plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - TROX	stocknewsapi	TROX
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Tronox Holdings plc ("Tronox" or "the Company") (NYSE: TROX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of TROX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: February 12, 2025 to July 30, 2025 DEADLINE: November 3, 2025 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Tronox suffered from declining sales and increased costs despite its overly optimistic sales projections. Based on these facts, Tronox's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate . NEXT STEPS FOR SHAREHOLDERS : Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 Email: [email protected] SOURCE DJS Law Group LLP
	2025-11-03 07:20 4mo ago	2025-11-03 02:14 4mo ago	LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm	stocknewsapi	LNTH
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ: LNTH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 26, 2025, and August 5, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before November 10, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Lantheus misled investors about the growth of Pylarify, its prostate cancer imaging product. The Company touted Pylarify's market leadership position and downplayed competitive pressures that were eating into its market position. The Company suffered sharp sales declines, revealing the truth of Pylarify's position in the market. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Lantheus, investors suffered damages. Join the case to recover your losses The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq., www.schallfirm.com Office: 310-301-3335 [email protected] SOURCE The Schall Law Firm
	2025-11-03 07:20 4mo ago	2025-11-03 02:16 4mo ago	VFC Investors Have Opportunity to Lead V.F. Corporation Securities Fraud Lawsuit with the Schall Law Firm	stocknewsapi	VFC
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against V.F. Corporation ("VF" or "the Company") (NYSE: VFC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 30, 2023 and May 20, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. VF promised investors its revenue outlook was reliable and minimized the risk of seasonality and macroeconomic fluctuations. The Company's positivity on growth as well as cost-cutting measures had no basis in reality. Based on these facts, the Company's public statements were false and materially misleading. When the market learned the truth about VF, investors suffered damages. Join the case to recover your losses The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq., www.schallfirm.com Office: 310-301-3335 [email protected] SOURCE The Schall Law Firm
	2025-11-03 07:20 4mo ago	2025-11-03 02:18 4mo ago	Nebius Stock Powers Up Ahead Of Key Q3 Test	stocknewsapi	NBIS
SummaryNebius has surged 140% in three months, driven by its unique position as a vertically integrated AI infrastructure provider.NBIS boasts a robust Microsoft partnership, deep Nvidia integration, and industry-leading efficiency, supporting a strong moat and rapid ARR growth.Q3 earnings are key, with investors watching utilization, ARR guidance, and enterprise client traction to justify NBIS's premium valuation.Risks include heavy capital needs, reliance on Microsoft, and execution challenges, but current momentum and execution support a bullish outlook into Q3. mustafaU/iStock via Getty Images Elevator Thesis I covered Nebius (NBIS) stock back in September, and unsurprisingly, the stock’s up. However, I didn’t quite expect it to run as far as it did (44%, to be exact), having gained an eye-watering 140% in just the past three months. Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. Recommended For You
	2025-11-03 06:20 4mo ago	2025-11-03 00:00 4mo ago	Should You Buy or Sell Nvidia Stock?	stocknewsapi	NVDA
Nvidia stock has surged 1,400% over the last three years. While shares have gained significantly, the company still has several catalysts on the horizon.
	2025-11-03 06:20 4mo ago	2025-11-03 00:15 4mo ago	Prediction: These Stocks Could Deliver Market-Beating Returns Over the Next Decade	stocknewsapi	NBIS TSLA
Artificial intelligence (AI) has been a key theme in driving the stock market higher for years now. Over the last 10 years, the Nasdaq Composite (NASDAQINDEX: ^IXIC) and S&P 500 (SNPINDEX: ^GSPC) have posted total returns of 415% and 297%, respectively. ^IXIC data by YCharts As these trends illustrate, much of these gains occurred after 2020 -- on the backdrop of rising domestic infrastructure spend and, of course, accelerating investment in artificial intelligence (AI). Over the next decade, I suspect that AI will remain a core driver of economic growth. While there are countless ways to gain exposure to the AI revolution, two names in particular stand out to me. I'll break down why I think Tesla (TSLA +3.74%) and Nebius Group (NBIS +5.36%) could deliver market-beating returns over the next 10 years. 1. Tesla: Bringing autonomy to artificial intelligence (AI) Tesla is a pioneer in the electric vehicle (EV) movement, as well as an early developer of next-generation green energy products. However, for the last several years, CEO Elon Musk has been outlining his vision for Tesla to become more of a tech-enabled services business. Musk's ambition to evolve Tesla into a technology enterprise can be summed up in one word: autonomy. Musk is laser focused on adding a new layer to Tesla's existing automotive footprint. Specifically, he has his eyes set on the ride-hailing and delivery services markets. Tesla's goal is to create a global fleet of self-driving vehicles -- a new business venture known as Robotaxi. In theory, Robotaxi represents a transformative shift in Tesla's car business because it represents a high-margin, recurring revenue source of demand as opposed to one-time vehicle sales. Beyond autonomous vehicles, Tesla is also building a line of humanoid robots -- dubbed Optimus. The goal of these robots is to assist the human labor force in areas such as logistics, warehousing, and potentially even in retail settings. Musk himself is incredibly bullish on Optimus, signaling that 80% of Tesla's future value could one day come from the robotics segment. While Tesla is not the only company competing for market share in the autonomous vehicle and humanoid robotics industries, it stands out as one of the few big tech players developing both services internally. In the long run, this vertically integrated approach could translate to unparalleled competitive advantages over more fragmented systems. It's this dynamic that has some on Wall Street saying Tesla has unmatched optionality as the company looks to commercialize its AI roadmap. If the company is able to execute on these endeavors, Tesla could be on the brink of a lucrative combination: accelerating sales from both consumers and enterprises, matched with widening profit margins. As a longtime Tesla bull, I remain optimistic over Musk's ability to scale these new applications and usher in a wave of prolonged growth and industry-leading unit economics within the next decade. Image source: Getty Images. 2. Nebius Group: Dominating the intersection of chips, cloud, and AI infrastructure If you aren't familiar with Nebius Group, I wouldn't be surprised. The company only took to the Nasdaq exchange last year, following a spinoff from its parent company, Yandex. Nebius operates across four areas: cloud infrastructure, autonomous vehicles, AI services, and educational technology. This diversification echoes that of Amazon, another technology darling whose ecosystem spans numerous end markets. The company's core driver of growth, however, stems from its data center operation. Thanks to close ties with Nvidia, Nebius is able to procure high-performance GPUs and quickly outfit the hardware into data centers. Today's Change ( 5.36 %) $ 6.65 Current Price $ 130.83 From there, the company rents access to its AI accelerators through a cloud-based platform. This business model is known as a neocloud -- it essentially offers companies the flexibility to use advanced chips on-demand without needing to invest in capital-intensive infrastructure up front. Recently, Nebius signed a $17.4 billion cloud infrastructure deal with Microsoft -- signaling just how critical neoclouds are becoming as hyperscalers invest heavily to meet surging AI capacity demand. As AI infrastructure spending accelerates and more advanced applications across robotics and autonomous systems are on the horizon, Nebius stands out as one of the few companies well-positioned to benefit from the tailwinds at this intersection. By the next decade, Nebius could easily be a household name and emerge as one of AI's next big superstars. Adam Spatacco has positions in Amazon, Microsoft, Nvidia, and Tesla. The Motley Fool has positions in and recommends Amazon, Microsoft, Nvidia, and Tesla. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
	2025-11-03 06:20 4mo ago	2025-11-03 00:20 4mo ago	S&P 500 Earnings: Check The S&P 500 EPS Revisions For 2027	stocknewsapi	IVV SPLG SPXL SPY SSO UPRO VOO
SummaryThe forward 4-quarter estimate this week jumped to $294.87 from last week's $294.81 and August 1st’s $281.15.The S&P 500 has seen positive revisions in the 2027 EPS estimate since August 1, ’25.If the S&P 500 benchmark just meets that EPS growth target in ’26 and returns 14%, it will be the fourth year in a row of mid-teens or better returns for the benchmark, with ’23 and ’24 returns being 25% each.Higher S&P 500 estimates from positive revisions, gradually declining short-term interest rates from an easier Fed, and a pro-business Administration in Washington all represent tailwinds for solid market returns. ArtistGNDphotography/E+ via Getty Images It’s hard to be bearish when investors are seeing S&P 500 calendar year EPS estimates get revised like this: (Source: LSEG) Note the positive revisions in the 2027 EPS estimate since August 1, ’25. Someone Recommended For You
	2025-11-03 06:20 4mo ago	2025-11-03 00:30 4mo ago	Meet the Supercharged Artificial Intelligence (AI) Growth Stock That Could Join Apple, Nvidia, and Microsoft in the $3 Trillion Club by 2027	stocknewsapi	TSM
This company is the main supplier of semiconductors powering the entire AI revolution. Many investors know the "Magnificent Seven" tech companies that are powering the boom in artificial intelligence (AI) spending. But there is another company that supplies the majority of computer chips to the AI industry. That company is Taiwan Semiconductor Manufacturing (TSM 0.92%), or TSMC for short. It has built up a dominant position in manufacturing advanced computer chips for virtually all the Magnificent Seven and now has a market cap of $1.5 trillion. But shares may still be underrated by Wall Street. Here's why TSMC could double its market cap over the next two years and be worth $3 trillion by 2027 riding the back of AI infrastructure spending. The supplier of the entire AI revolution Data center builders plan to spend trillions of dollars over the next few years on AI. Much of this will go to chipmakers like Nvidia. However, Nvidia does not actually manufacture its own chips; TSMC does. This gives TSMC a dominant position in the AI supply chain. It is one of the few companies -- if not the only one -- able to produce the most advanced computer chips for all sorts of AI customers, giving it close to a monopoly in the semiconductor foundry space. This is why the company has grown its revenue by 335% in the last 10 years to $116 billion. Given its near monopoly, the chip manufacturer has abundant pricing power. Last quarter, TSMC posted an operating margin of over 50%, which is unheard of for a manufacturing business. Today's Change ( -0.92 %) $ -2.79 Current Price $ 300.43 As AI spending grows, so will the need for semiconductor capacity from TSMC. This should enable it to keep increasing revenue rapidly -- 41% year over year last quarter -- and perhaps eclipse $200 billion in sales in 2027. With a 50% operating margin, that would equate to $100 billion in bottom-line operating earnings. Image source: Taiwan Semiconductor Manufacturing. Betting on America and reinvesting for growth Taiwan is the hub of semiconductor manufacturing, but given the country's geopolitical risk due to its relationship with China, TSMC and the U.S. government -- along with TSMC customers such as Apple and Nvidia -- have made a big push to build semiconductor factories in the U.S. TSMC is expecting to have $165 billion in capital expenditures in the U.S. for advanced manufacturing plants, centered in Arizona. The company would make such an investment only if it knows it will directly lead to growth, which should show that it believes it can keep up its impressive pace of AI deployments. Sam Altman, CEO of OpenAI, has said that he wants Taiwan Semiconductor to increase its manufacturing capacity as quickly as possible. Even though TSMC's revenue is growing at 40% year over year, its pace of adding semiconductor supply is still well below overall market demand. Can TSMC achieve a $3 trillion market cap? Unlike most Magnificent Seven stocks, TSMC trades at a reasonable valuation with a price-to-earnings ratio (P/E) of 31. This figure should come down quickly as the company keeps scaling up its manufacturing in both Taiwan and the U.S. If TSMC can grow its revenue at 40% for the next two years, it will have around double the sales it does today in 2027. Using our $100 billion earnings estimate from above and a P/E of 30, TSMC stock would therefore trade at a market cap of $3 trillion by 2027. Of course, the company may face some margin pressure, slowing growth, or a multiple compression that will impact its ability to generate these quick returns for shareholders. Regardless, the stock looks cheap for investors who want to buy and hold for the long term. TSMC is a great company and should remain a great company through the ups and downs of the AI infrastructure cycle.
	2025-11-03 06:20 4mo ago	2025-11-03 00:55 4mo ago	Exclusive: ExxonMobil CEO warns EU sustainability law could end Europe operations	stocknewsapi	XOM
By Reuters November 3, 20255:55 AM UTCUpdated ago Darren Woods, CEO of ExxonMobil, speaks at the Asia-Pacific Economic Cooperation (APEC) CEO Summit in San Francisco, California, U.S., November 15, 2023. REUTERS/Carlos Barria Purchase Licensing Rights, opens new tab CompaniesABU DHABI, Nov 3 (Reuters) - ExxonMobil CEO Darren Woods told Reuters on Monday it will be impossible for the energy giant to continue doing business in Europe if the European Union doesn't make significant changes to a sustainability law that threatens to penalize companies with fines of 5% of global revenue. Woods said EU lawmakers are listening to opposition to the law, but he has not seen significant changes to it yet. Sign up here. Reporting by Andrew Mills; Editing by Tom Hogue Our Standards: The Thomson Reuters Trust Principles., opens new tab
	2025-11-03 06:20 4mo ago	2025-11-03 00:58 4mo ago	China Eastern Airlines Unveils 2025 Winter-Spring Schedule, Set to Launch the World's Longest Route	stocknewsapi	CHEAF
SHANGHAI--(BUSINESS WIRE)--From October 26, China Eastern Airlines (CEA) officially implemented its 2025 winter-spring flight schedule. In this new season, the airline will operate with 820 aircraft, covering 39 countries and 253 domestic and international destinations, including 88 overseas destinations. It will run about 3,130 flights per day, with an average of 3,220 international and regional flights per week. As this season aligns with the Southern Hemisphere's midsummer, New Zealand, Australia, and Southeast Asia emerge as top winter sun destinations. To meet passengers' diversified travel needs, CEA is continuously opening new routes and increasing frequencies on international and regional services to further enhance connectivity. CEA has launched new routes, including Beijing–Muscat and Shanghai–Auckland–Buenos Aires, resumed the Shanghai–Delhi service, and increased frequencies on popular routes such as Shanghai–Hanoi, Xi'an–Phu Quoc, Kunming–Vientiane, and Kunming–Phnom Penh. High-frequency international express flights from Bangkok, Singapore, and other cities to Shanghai remain in operation, providing international travelers with efficient, convenient transit services. They also offer connections to popular Chinese winter destinations, including Harbin, Changchun, Shenyang, and Changbai Mountain, where travelers can experience the unique charm of China's ice-and-snow tourism. In the new season, CEA's "Air Express" network will expand to 49 routes, with an average of about 899 flights per day, covering major hubs such as Shanghai, Beijing, and Guangzhou. The busiest Beijing–Shanghai Express alone will operate 66 round-trip flights daily, essentially offering daytime departures every hour and half hour. In addition, as the global launch customer of the C919, CEA has deployed all 11 of its C919 aircraft into the new season, operating 12 routes across 10 cities via 11 airports. Notably, CEA will inaugurate the Shanghai–Auckland–Buenos Aires route on December 4, 2025. Covering 20,000 kilometers, the service will connect the Eastern and Western Hemispheres as well as the Northern and Southern Hemispheres, becoming the world's first commercial route linking antipodal cities and the world's longest single flight.
	2025-11-03 06:20 4mo ago	2025-11-03 01:00 4mo ago	Positive Phase III Data for Genentech's Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus	stocknewsapi	RHHBY
– Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion – – Gazyva has the potential to be a transformative new standard of care for up to 3.4 million people affected by systemic lupus erythematosus (SLE) worldwide – – If approved, Gazyva would be the first anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity – – These positive results follow the recent U.S. FDA approval and positive EU CHMP opinion for Gazyva in lupus nephritis, alongside positive Phase III data from the INShore study in idiopathic nephrotic syndrome – SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from the Phase III ALLEGORY study of Gazyva® (obinutuzumab) in adults with systemic lupus erythematosus (SLE) on standard therapy. The study met its primary endpoint showing a higher percentage of people achieved a minimum four-point improvement in SLE Responder Index 4 (SRI-4) at one year (52 weeks) with Gazyva versus standard therapy. SRI is a tool that assesses changes in disease severity, symptoms and physical condition to indicate whether treatment is effective at controlling disease activity. All key secondary endpoints were also met. No new safety signals were identified, and safety was in line with the well-characterized profile of Gazyva. “Systemic lupus erythematosus is a lifelong condition that can cause irreversible damage to the major organs in the body, leading to life-threatening complications. These pivotal results are unprecedented in demonstrating that by effectively controlling disease activity, Gazyva may delay or prevent further organ damage in people with SLE,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We look forward to sharing the data with global health authorities, with the goal of making this potentially transformative new standard of care available as quickly as possible.” All key secondary endpoints were met, with results showing statistically significant and clinically meaningful benefits with Gazyva versus standard therapy including British Isles Lupus Assessment Group based Composite Lupus Assessment (BICLA) response at week 52, sustained corticosteroid control from week 40 to 52, sustained SRI-4 from week 40 to 52, a six-point improvement in SLE disease activity score (SRI-6) at 52 weeks, and time to first flare over 52 weeks as defined by the British Isles Lupus Assessment Group (BILAG) index. SLE affects over three million people worldwide, mostly women diagnosed between the ages of 15 and 45, with women of color disproportionately impacted. Frequent flares of disease activity inflame and damage multiple organs. Around half of the patients will progress to lupus nephritis, a potentially life-threatening kidney complication, within five years of diagnosis. Achieving better disease control can reduce flares, limit further damage to the organs and lower the risk of developing lupus nephritis. Data will be presented at an upcoming medical meeting and shared with health authorities as soon as possible, including the U.S. Food and Drug Administration and the European Medicines Agency. If approved, Gazyva would be the first anti-CD20 therapy for SLE to directly target B cells, an underlying cause of disease. ALLEGORY is the third positive Phase III study for Gazyva in immune-mediated diseases, in addition to REGENCY in lupus nephritis and INShore in idiopathic nephrotic syndrome. This growing evidence suggests that Gazyva, designed to attack and destroy targeted B cells, both directly and together with the body's immune system, may help address disease activity across a spectrum of autoimmune or immune-related diseases. In addition to SLE, Gazyva is being investigated in children and adolescents with lupus nephritis, as well as adults with membranous nephropathy, as part of our ambition to be leaders in immune-mediated rheumatology and nephrology diseases. About Gazyva Gazyva® (obinutuzumab) is a humanized monoclonal antibody designed with a Type II anti-CD20 region, for direct B cell death and a glycoengineered Fc region, for higher binding affinity and increased antibody-dependent cellular cytotoxicity (ADCC). CD20 is a protein found on certain types of B cells. Gazyva is approved for adults with lupus nephritis in the U.S. who are receiving standard therapy. In October 2025, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval in the European Union, with a final decision expected from the European Commission in the near future. Gazyva is also approved in 100 countries for various types of hematological cancers. About the ALLEGORY Study ALLEGORY [NCT04963296] is a Phase III, randomized, double-blind, placebo-controlled, multicenter study, investigating the efficacy and safety of Gazyva® (obinutuzumab) compared with standard therapy in adults with systemic lupus erythematosus (SLE) on standard therapy. The study enrolled approximately 300 people, who were randomized 1:1 to receive Gazyva or placebo for up to one year (52 weeks), followed by an open-label period with Gazyva for up to 104 weeks. The primary endpoint is the percentage of people who achieve SLE Responder Index four at week 52. About Systemic Lupus Erythematosus Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease that affects more than three million people worldwide, and rising. Due to the non-specific symptoms, it can take two to six years for an accurate diagnosis. During this time, disease severity and organ damage, due to repeated flares of disease activity, typically worsens and quality of life declines. Around half of people with SLE will develop lupus nephritis within five years of a lupus diagnosis. In lupus nephritis, the disease activity primarily affects the kidneys and there is a risk of end-stage kidney disease, where dialysis and transplant are the only treatment options. There is a need for additional targeted therapies that can effectively control disease activity and potentially delay or prevent the onset of lupus nephritis. GAZYVA Indications GAZYVA® (obinutuzumab) is a prescription medicine used: With the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous CLL treatment With the chemotherapy drug, bendamustine, followed by GAZYVA alone for follicular lymphoma (FL) in adults who did not respond to a rituximab-containing regimen, or whose FL returned after such treatment With chemotherapy, followed by GAZYVA alone in those who responded, to treat stage II bulky, III, or IV FL in adults who have not had previous FL treatment for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy Important Safety Information The most important safety information patients should know about GAZYVA Patients must tell their doctor right away about any side effect they experience. GAZYVA can cause side effects that can become serious or life-threatening, including: Hepatitis B Virus (HBV): Hepatitis B can cause liver failure and death. If the patient has a history of hepatitis B infection, GAZYVA could cause it to return. Patients should not receive GAZYVA if they have active hepatitis B liver disease. The patient’s doctor or healthcare team will need to screen them for hepatitis B before, and monitor the patient for hepatitis during and after, their treatment with GAZYVA. Sometimes this will require treatment for hepatitis B. Symptoms of hepatitis include: worsening of fatigue and yellow discoloration of skin or eyes Progressive Multifocal Leukoencephalopathy (PML): PML is a rare and serious brain infection caused by a virus. PML can be fatal. The patient’s weakened immune system could put them at risk. The patient’s doctor will watch for symptoms. Symptoms of PML include: confusion, difficulty talking or walking, dizziness or loss of balance, and vision problems Who should not receive GAZYVA: Patients should NOT receive GAZYVA if they have had an allergic reaction (e.g., anaphylaxis or serum sickness) to GAZYVA. Patients must tell their healthcare provider if they have had an allergic reaction to obinutuzumab or any other ingredients in GAZYVA in the past. Additional possible serious side effects of GAZYVA: Patients must tell their doctor right away about any side effect they experience. GAZYVA can cause side effects that may become severe or life-threatening, including: Infusion-Related Reactions: These side effects may occur during or within 24 hours of any GAZYVA infusion. Some infusion-related reactions can be serious, including, but not limited to, severe allergic reactions (anaphylaxis), acute life-threatening breathing problems, or other life-threatening infusion-related reactions. If the patient has a reaction, the infusion is either slowed or stopped until their symptoms are resolved. Most patients are able to complete infusions and receive medication again. However, if the infusion-related reaction is life-threatening, the infusion of GAZYVA will be permanently stopped. The patient’s healthcare team will take steps to help lessen any side effects the patient may have to the infusion process. The patient may be given medicines to take before each GAZYVA treatment. Symptoms of infusion-related reactions may include: fast heartbeat, tiredness, dizziness, headache, redness of the face, nausea, chills, fever, vomiting, diarrhea, rash, high blood pressure, low blood pressure, difficulty breathing, and chest discomfort Hypersensitivity Reactions Including Serum Sickness: Some patients receiving GAZYVA may have severe or life-threatening allergic reactions. This reaction may be severe, may happen during or after an infusion, and may affect many areas of the body. If an allergic reaction occurs, the patient’s doctor will stop the infusion and permanently discontinue GAZYVA Tumor Lysis Syndrome (TLS): Tumor lysis syndrome, including fatal cases, has been reported in patients receiving GAZYVA. GAZYVA works to break down cancer cells quickly. As cancer cells break apart, their contents are released into the blood. These contents may cause damage to organs and the heart and may lead to kidney failure requiring the need for dialysis treatment. The patient’s doctor may prescribe medication to help prevent TLS. The patient’s doctor will also conduct regular blood tests to check for TLS. Symptoms of TLS may include nausea, vomiting, diarrhea, and tiredness. TLS is not identified as a risk in LN Serious, Including Fatal, Infections: While the patient is taking GAZYVA, they may develop infections. Some of these infections may be fatal and severe, so the patient should be sure to talk to their doctor if they think they have an infection. Patients administered GAZYVA in combination with chemotherapy, followed by GAZYVA alone are at a high risk of infections during and after treatment. Patients with a history of recurring or chronic infections may be at an increased risk of infection. Patients taking GAZYVA plus standard therapy may be at higher risk for fatal or severe infections compared to patients taking standard therapy plus placebo. Patients with an active infection should not be treated with GAZYVA. Patients taking GAZYVA plus bendamustine may be at higher risk for fatal or severe infections compared to patients taking GAZYVA plus CHOP or CVP. If the patient develops a serious infection, your doctor will immediately discontinue GAZYVA and begin treatment for the infection. Low White Blood Cell Count: When the patient has an abnormally low count of infection-fighting white blood cells, it is called neutropenia. While the patient is taking GAZYVA, their doctor will do blood work to check their white blood cell count. Severe and life-threatening neutropenia can develop during or after treatment with GAZYVA. Some cases of neutropenia can last for more than one month. If the patient’s white blood cell count is low, their doctor may prescribe medication to help prevent infections Low Platelet Count: Platelets help stop bleeding or blood loss. GAZYVA may reduce the number of platelets the patient has in their blood; having low platelet count is called thrombocytopenia. This may affect the clotting process. While the patient is taking GAZYVA, their doctor will do blood work to check their platelet count. Severe and life-threatening thrombocytopenia can develop during treatment with GAZYVA. Fatal bleeding events have occurred in patients treated with GAZYVA. If the patient’s platelet count gets too low, their treatment may be delayed or reduced Disseminated Intravascular Coagulation (DIC): Fatal and severe DIC has been reported in people receiving GAZYVA. DIC is a rare and serious abnormal blood clotting condition that should be monitored and managed by the patient’s doctor as it can lead to uncontrollable bleeding The most common side effects of GAZYVA in CLL were infusion-related reactions and low white blood cell counts. The most common side effects seen with GAZYVA in a study that included relapsed or refractory NHL, including FL patients were infusion-related reactions, fatigue, low white blood cell counts, cough, upper respiratory tract infection, and joint or muscle pain. The most common side effects seen with GAZYVA in a study that included previously untreated FL patients were infusion-related reactions, low white blood cell count, upper respiratory tract infections, cough, constipation and diarrhea. The most common side effects of GAZYVA in LN were upper respiratory tract infection, COVID-19, urinary tract infection, bronchitis, pneumonia, infusion infusion-related reactions, and neutropenia. Before receiving GAZYVA, patients should talk to their doctor about: Immunizations: Before receiving GAZYVA therapy, the patient should tell their healthcare provider if they have recently received or are scheduled to receive a vaccine. Patients who are treated with GAZYVA should not receive live vaccines Pregnancy: The patient should tell their doctor if they are pregnant, think that they might be pregnant, plan to become pregnant, or are breastfeeding. GAZYVA may harm their unborn baby. The patient should speak to their doctor about using GAZYVA while they are pregnant. The patient should talk to their doctor or their child’s doctor about the safety and timing of live virus vaccinations to their infant if they received GAZYVA during pregnancy. Women of childbearing potential should use effective contraception while taking GAZYVA and for 6 months after your GAZYVA treatment Breastfeeding: Because of the potential risk of serious side reactions in breastfed children, patients should not breastfeed while taking GAZYVA and for 6 months after your last dose Patients should tell their doctor about any side effects. These are not all of the possible side effects of GAZYVA. For more information, patients should ask their doctor or pharmacist. GAZYVA is available by prescription only. Report side effects to the FDA at (800) FDA-1088, or http://www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555. Please visit https://www.GAZYVA.com for the GAZYVA full Prescribing Information, including BOXED WARNINGS, for additional Important Safety Information. About Genentech in Immunology Genentech is committed to harnessing pioneering science and innovation to address critical unmet needs for patients with immune-mediated inflammatory diseases. Our pipeline includes over a dozen clinical programs in immunology aiming to transform care for people living with lupus, MASH, ulcerative colitis, Crohn’s disease, immunoglobulin A nephropathy, idiopathic nephrotic syndrome, atopic dermatitis, and rheumatoid arthritis. We are investing end-to-end in immunology from discovery and R&D to commercialization across a variety of modalities including monoclonal antibodies, bispecifics, and CAR-T cell therapies to help solve some of the most difficult challenges in immunology today. About Genentech Founded nearly 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
	2025-11-03 06:20 4mo ago	2025-11-03 01:00 4mo ago	RLX Technology to Report Third Quarter 2025 Financial Results on November 14, 2025	stocknewsapi	RLX
- Earnings Call Scheduled for 7:00 a.m. ET on November 14, 2025 - , /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE: RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025, before the U.S. markets open on Friday, November 14, 2025. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 14, 2025 (8:00 PM Beijing/Hong Kong Time on November 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Kong, China (toll free): +800-963-976 Hong Kong, China: +852-5808-1995 Mainland China: 400-120-6115 Participant Code ( English line): 2869014 Participant Code ( Chinese simultaneous interpretation line): 7381962 Participants can choose between the English and Chinese simultaneous interpretation options as above to join the conference call. Please note that the Chinese simultaneous interpretation option is in listen-only mode. Participants should dial-in 10 minutes before the scheduled start time and ask to be connected to the call for "RLX Technology Inc." with the English or Chinese Participant Code as set forth above. Additionally, a live and archived webcast of the conference call will be available on the Company's investor relations website at https://ir.relxtech.com. A replay of the conference call will be accessible approximately two hours after the conclusion of the call until November 21, 2025, by dialing the following telephone numbers: United States: +1-877-344-7529 International: +1-412-317-0088 Replay Access Code (English line): 5641887 Replay Access Code (Chinese line): 4042658 About RLX Technology Inc. RLX Technology Inc. (NYSE: RLX) is a leading global branded e-vapor company. The Company leverages its strong in-house technology, and product development capabilities and in-depth insights into adult smokers' needs to develop superior e-vapor products. For more information, please visit https://ir.relxtech.com. Contacts In China: RLX Technology Inc. Head of Capital Markets Sam Tsang Email: [email protected] Piacente Financial Communications Jenny Cai Tel: +86-10-6508-0677 Email: [email protected] In the United States: Piacente Financial Communications Brandi Piacente Tel: +1-212-481-2050 Email: [email protected] SOURCE RLX Technology Inc.
	2025-11-03 06:20 4mo ago	2025-11-03 01:00 4mo ago	Positive phase III data for Roche's Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus	stocknewsapi	RHHBY
Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletionGazyva/Gazyvaro has the potential to be a transformative new standard of care for up to 3.4 million people affected by systemic lupus erythematosus (SLE) worldwideIf approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity1These positive results follow the recent US FDA approval and positive EU CHMP opinion for Gazyva/Gazyvaro in lupus nephritis, alongside positive phase III data from the INShore study in idiopathic nephrotic syndrome Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the phase III ALLEGORY study of Gazyva®/Gazyvaro® (obinutuzumab) in adults with systemic lupus erythematosus (SLE) on standard therapy. The study met its primary endpoint showing a higher percentage of people achieved a minimum four-point improvement in SLE Responder Index 4 (SRI-4) at one year (52 weeks) with Gazyva/Gazyvaro versus standard therapy.2 SRI is a tool that assesses changes in disease severity, symptoms and physical condition to indicate whether treatment is effective at controlling disease activity. All key secondary endpoints were also met. No new safety signals were identified, and safety was in line with the well-characterised profile of Gazyva/Gazyvaro. “Systemic lupus erythematosus is a lifelong condition that can cause irreversible damage to the major organs in the body, leading to life-threatening complications. These pivotal results are unprecedented in demonstrating that by effectively controlling disease activity, Gazyva/Gazyvaro may delay or prevent further organ damage in people with SLE,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “We look forward to sharing the data with global health authorities, with the goal of making this potentially transformative new standard of care available as quickly as possible.” All key secondary endpoints were met, with results showing statistically significant and clinically meaningful benefits with Gazyva/Gazyvaro versus standard therapy including British Isles Lupus Assessment Group based Composite Lupus Assessment (BICLA) response at week 52, sustained corticosteroid control from week 40 to 52, sustained SRI-4 from week 40 to 52, a six-point improvement in SLE disease activity score (SRI-6) at 52 weeks, and time to first flare over 52 weeks as defined by the British Isles Lupus Assessment Group (BILAG) index.1 SLE affects over three million people worldwide, mostly women diagnosed between the ages of 15 and 45, with women of colour disproportionately impacted.3-5 Frequent flares of disease activity inflame and damage multiple organs. Around half of the patients will progress to lupus nephritis, a potentially life-threatening kidney complication, within five years of diagnosis.6-8 Achieving better disease control can reduce flares, limit further damage to the organs and lower the risk of developing lupus nephritis.9,10 Data will be presented at an upcoming medical meeting and shared with health authorities as soon as possible, including the US Food and Drug Administration and the European Medicines Agency. If approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy for SLE to directly target B cells, an underlying cause of disease.2 ALLEGORY is the third positive phase III study for Gazyva/Gazyvaro in immune-mediated diseases, in addition to REGENCY in lupus nephritis and INShore in idiopathic nephrotic syndrome. This growing evidence suggests that Gazyva/Gazyvaro, designed to attack and destroy targeted B cells, both directly and together with the body's immune system, may help address disease activity across a spectrum of autoimmune or immune-related diseases. In addition to SLE, Gazyva/Gazyvaro is being investigated in children and adolescents with lupus nephritis, as well as adults with membranous nephropathy, as part of our ambition to be leaders in immune-mediated rheumatology and nephrology diseases. About Gazyva/Gazyvaro Gazyva®/Gazyvaro® (obinutuzumab) is a humanised monoclonal antibody designed with a Type II anti-CD20 region, for direct B cell death and a glycoengineered Fc region, for higher binding affinity and increased antibody-dependent cellular cytotoxicity (ADCC).11 CD20 is a protein found on certain types of B cells. Gazyva/Gazyvaro is approved for adults with lupus nephritis in the US who are receiving standard therapy. In October 2025, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval in the European Union, with a final decision expected from the European Commission in the near future. Gazyva/Gazyvaro is also approved in 100 countries for various types of haematological cancers. About the ALLEGORY study ALLEGORY [NCT04963296] is a phase III, randomised, double-blind, placebo-controlled, multicentre study, investigating the efficacy and safety of Gazyva®/Gazyvaro® (obinutuzumab) compared with standard therapy in adults with systemic lupus erythematosus (SLE) on standard therapy. The study enrolled approximately 300 people, who were randomised 1:1 to receive Gazyva/Gazyvaro or placebo for up to one year (52 weeks), followed by an open-label period with Gazyva/Gazyvaro for up to 104 weeks. The primary endpoint is the percentage of people who achieve SLE Responder Index four at week 52. About systemic lupus erythematosus Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease that affects more than three million people worldwide, and rising.3,12 Due to the non-specific symptoms, it can take two to six years for an accurate diagnosis. During this time, disease severity and organ damage, due to repeated flares of disease activity, typically worsens and quality of life declines.9,13,14 Around half of people with SLE will develop lupus nephritis within five years of a lupus diagnosis.7,8 In lupus nephritis, the disease activity primarily affects the kidneys and there is a risk of end-stage kidney disease, where dialysis and transplant are the only treatment options. There is a need for additional targeted therapies that can effectively control disease activity and potentially delay or prevent the onset of lupus nephritis.15,16 About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Yap DYH, Chan TM. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments. Int J Mol Sci. 2019 Dec 10;20(24):6231. [2] Clinicaltrials.gov. A study to evaluate the efficacy and safety of obinutuzumab in participants with systemic lupus erythematosus (ALLEGORY). [Internet; cited 2025 October 30]. Available from: https://clinicaltrials.gov/study/NCT04963296. [3] Tian J, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023 Mar;82(3):351-56. [4] Bindroo MA, et al. Late Onset Systemic Lupus Erythematosus - Clinical and Autoantibody Profile and its Comparison with Young Onset Systemic Lupus Erythematosus. Mediterr J Rheumatol. 2023 Jul 29;34(4):454–59 [5] Barber MRW, et al. The global epidemiology of SLE: narrowing the knowledge gaps. Rheumatology (Oxford). 2023 Mar 29;62(Suppl 1):i4-9 [6] Mahajan A, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 2020 Sep;29(9):1011-20. [7] Bechler KK, et al. Predicting patients who are likely to develop Lupus Nephritis of those newly diagnosed with Systemic Lupus Erythematosus. AMIA Annu Symp Proc. 2023 Apr 29:2022:221-30. [8] Anders HJ et al. Lupus nephritis. Nat Rev Dis Primers. 2020 Jan 23;6(1):7. [9] Kandane-Rathnayake R, et al. Association of Lupus Low Disease Activity State And Remission With Reduced Organ Damage And Flare in Systemic lupus erythematosus Patients With High Disease Activity. Rheumatology (Oxford). 2025 May 1;64(5):2741-48. [10] Adamichou C, et al. Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. Mediterr J Rheumatol. 2017 Mar 28;28(1):4-12. [11] Herter S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013 Oct;12(10):2031-42. [12] Rees F, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017 Nov 1;56(11):1945-61. [13] Nightingale AL, et al. Presentation of SLE in UK primary care using the Clinical Practice Research Datalink. Lupus Sci Med. 2017 Feb 10;4(1):e000172. [14] Murimi-Worstell IB, et al. Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis. BMJ Open. 2020 May 21;10(5):e031850. [15] Hocaoglu M et al. Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades using the Lupus Midwest Network. Arthritis & Rheumatol 2023 Apr;75(4):567-73. [16] Mok C, et al. Treatment of lupus nephritis: consensus evidence and perspectives. Nat Rev Rheumatol. 2023 Apr;19(4):227-38. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: [email protected] Hans Trees, PhD Phone: +41 79 407 72 58 Sileia Urech Phone: +41 79 935 81 48 Nathalie Altermatt Phone: +41 79 771 05 25 Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +49 172 6367262 Yvette Petillon Phone: +41 79 961 92 50 Dr Rebekka Schnell Phone: +41 79 205 27 03 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: [email protected] Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: [email protected] Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: [email protected] Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: [email protected] Media Investor Release Gazyva ALLEGORY study English
	2025-11-03 06:20 4mo ago	2025-11-03 01:00 4mo ago	HIVE Digital Technologies Accelerates into the AI Super Cycle by Securing Prime Land for Next-Gen Tier III+ AI HPC Data Centers and Surpassing 23 EH/s	stocknewsapi	HIVE
November 03, 2025 1:00 AM EST \| Source: HIVE Digital Technologies Ltd. San Antonio, Texas--(Newsfile Corp. - November 3, 2025) - HIVE Digital Technologies Ltd. (TSXV: HIVE) (NASDAQ: HIVE) (FSE: YO0) (the "Company" or "HIVE"), a global leader in sustainable digital infrastructure, today announced a pivotal milestone in the heart of the AI super cycle: achieving 23 Exahash per second ("EH/s") in global Bitcoin-mining capacity-positioning the Company amongst industry leaders in 2025 with 283% year-to-date growth (all amounts in US dollars, unless otherwise indicated). In tandem, HIVE has finalized the acquisition of an additional 32.5 acres in Grand Falls, New Brunswick, adjacent to its existing operations, positioning the site as a cornerstone for Tier III+ HPC development capable of scaling to over 25,000 next-generation GPUs. With the AI industrial revolution demanding unprecedented compute power, HIVE's renewable-energy backbone is fast-tracking hyperscaler-ready infrastructure to fuel this global surge. Fueling the AI Super Cycle: Why HPC Data Centers Are the Backbone of Tomorrow's Economy The AI super cycle is here-propelled by breakthroughs in generative AI, machine learning, and real-time data processing that require exponentially more computational power than ever before. Traditional data centers are struggling to keep up with the requirements, as global demand for HPC is projected to skyrocket as companies from startups to Fortune 500 giants seek liquid-cooled, high-density facilities to deploy the world's most powerful GPU chips. Frank Holmes, Co-Founder and Executive Chairman, said, "HIVE is a pioneer in repurposing stranded and surplus renewable energy for digital infrastructure, and is now turbocharging the transition from Bitcoin mining Tier I to Tier III+ HPC data centers in Canada and Sweden. Its Tier III+ HPC expansions aren't just additions-they are strategic accelerators, delivering scalable, green-powered compute that slashes deployment timelines and costs for hyperscalers chasing the AI edge. HIVE's wholly owned HPC/AI subsidiary BUZZ HPC plans to scale its HPC data center capacity to support over 30,000 high-performance GPUs for AI cloud." HIVE Bolsters Canadian Footprint for AI-Driven HPC Expansion HIVE has completed its strategic land acquisition in Grand Falls, New Brunswick, adding 32.5 acres adjacent to the Company's existing 6-acre property acquired in April 2021. Purchased for CAD $2.3 million, this expanded site lays the groundwork for HIVE's inaugural Tier III+ AI and HPC data center in Atlantic Canada-a beacon for the region's clean-energy ecosystem near the border of Maine. Leveraging abundant renewable hydroelectric power, the Grand Falls facility currently powers 70 megawatts ("MW") of Bitcoin mining with an on-site 80 MW substation-all owned outright by HIVE, including the buildings. This acquisition unlocks vast potential for HPC growth, enabling HIVE's BUZZ subsidiary to scale its HPC data center capacity to over 30,000 GPUs. Its strategic proximity to the Maine border makes it an ideal candidate for hyperscaler colocation, bridging North American AI infrastructure needs with robust efficiency. Executive Perspectives: Pioneering the AI Industrial Revolution Craig Tavares, President & COO of BUZZ HPC, commented: "Grand Falls offers the ideal convergence of Tier I and Tier III+ HPC data centers with clean power, scalability, and community partnership. Our vision is to transform this site into one of Canada's most advanced Tier III+ AI HPC data centers, capable of hosting tens of thousands of GPUs for AI and HPC workloads. This marks an important step for BUZZ HPC, HIVE's Canadian company with a mission to deliver sustainable, high-density compute that fuels the AI industrial revolution." Aydin Kilic, President & CEO of HIVE, emphasized the Company's unique advantage in the AI super cycle: "Bitcoin miners like HIVE were early visionaries, sourcing stranded or surplus energy to build the foundational infrastructure that now fast-tracks hyperscalers in the AI industrial revolution. We're not just adapting-we're turbocharging a double-engine data-center machine, seamlessly building and upgrading Tier I and Tier III+ HPC facilities to unleash the most powerful GPU chips for AI workloads. With 23 EH/s already secured, we're generating robust cash flows today while scaling green HPC tomorrow in Canada and Paraguay, positioning HIVE as the go-to partner for the compute demands of this era." Luke Rossy, HIVE's COO, added: "Our Valenzuela facility continues to scale ahead of schedule, with new ASICs driving increased Bitcoin production and generating incremental cash flow to support strategic growth across HIVE's dual engines of Bitcoin mining and AI cloud computing. This approach maximizes return on invested capital, creates diversified value for shareholders, and reinforces HIVE's position as a renewable-powered, high-performance digital-infrastructure leader in the AI era." HIVE Powers Through to 23 EH/s Amid Soaring AI Compute Demand HIVE's ascent to 23 EH/s highlights the resilience of its global renewable portfolio, boasting an average efficiency of 17.7 J/TH-even as Bitcoin difficulty hits a record 156T and prices hover near $108,000, delivering over 50% mining margins* post-electricity costs. All ASICs and hydro-cooling containers are now deployed at the Company's third 100 MW green campus in Valenzuela, Paraguay, powered by the Itaipú Dam, the Western Hemisphere's largest hydroelectric facility. With commissioning underway, HIVE anticipates hitting 25 EH/s by U.S. Thanksgiving, targeting 17.5 J/TH efficiency and meeting its full 2025 hashrate goals on time. This momentum isn't isolated-it's symbiotic with the AI super cycle. Bitcoin mining's proven infrastructure provides immediate revenue to fund HPC upgrades, creating a virtuous loop where surplus energy powers both proof-of-work security and AI's growing data needs. Dual-Engine Strategy: Bridging Bitcoin and AI for Exponential Scale HIVE is advancing its Tier III+ HPC roadmap, converting its Boden, Sweden facility from Tier I to a liquid-cooled powerhouse. This retrofit leverages existing assets to slash timelines to 9-12 months-versus multiple years for greenfield builds-unlocking 2,000 high-performance GPUs for EU-based AI workloads upon launch. Complementing this, HIVE's BUZZ data-center acquisition in Toronto targets 2,000 GPUs for AI operations in 2026, with a Bell colocation partnership adding another 2,000 GPUs over the next nine months. By year-end 2026, HIVE projects 6,000 next generation high-performance GPUs operational in these new facilities, in addition to the current fleet of 5,000 GPUs HIVE operates. Factoring in Grand Falls' conversion from mining to HPC-with a PUE of 1.3-the site alone could operate 25,000 additional GPUs, pushing HIVE's long-term HPC data center capacity to approximately 36,000 GPUs. This accelerates HIVE's growth in the AI super cycle, where HPC data centers aren't optional-they're the indispensable engines of innovation. Operational Momentum and Shareholder Alignment As disclosed, Valenzuela's full hardware rollout is fully funded and on-site, with each incremental EH/s boosting Bitcoin output under stable, fixed-rate hydro costs. Results will fluctuate with network dynamics and market prices, but HIVE's model demonstrates the critical ability to scale while maintaining efficiency across its data centers in Canada, Sweden, and Paraguay. To champion its team's role in this AI-fueled ascent, HIVE is granting 2,720,900 Restricted Share Units (RSUs) to employees, officers, directors, and consultants under its RSU plan, with a mandatory one-year TSX Venture Exchange vesting period. This aligns management with investors to build long-term value. Inspired by Harvard Business School research on non-linear incentives, these quarterly milestone-based awards foster innovation and retention-aligning global talent from Paraguay to Sweden with HIVE's vision for sustainable growth and minimal dilution. HIVE has shared these RSUs with all employees, both new and long-serving, to preserve its unique culture with a focus on efficiency and return on invested capital. The Company now operates across nine time zones and five languages. Quarterly ATM Sales Report For the three-month period ended September 30, 2025, the Company issued 30,174,046 common shares (the "October 2024 ATM Shares") pursuant to the at-the-market offering commenced in October 2024 and continued in May 2025 (the "October 2024 ATM Equity Program") for gross proceeds of C$100.2 million ($73.1 million). The October 2024 ATM Shares were sold at prevailing market prices, for an average price per October 2024 ATM Share of C$3.32. Pursuant to the October 2024 ATM Equity program, a cash commission of $1.9 million on the aggregate gross proceeds raised was paid to the sales agents in connection with its services under the October 2024 ATM Equity Program. * As used herein, "Mining Margin" is calculated by dividing the mining profit (revenue generated from mining activities minus power costs related to those activities) by the total revenue generated from mining activities and expressed as a percentage. In mining, the most significant expense is power cost; in this estimate we are assuming an average of USD 5 cents per kilowatt hour for indicative purposes. These non-GAAP measures should be read in conjunction with and should not be viewed as alternatives to or replacements for measures of operating results and liquidity presented in accordance with GAAP in HIVE's quarterly and annual financial statements. All financial projections reflect current market sentiment and public disclosures as of the date of this news release; actual outcomes may vary. Investors should conduct their own due diligence. About HIVE Digital Technologies Ltd. Founded in 2017, HIVE Digital Technologies Ltd. is the first publicly listed company to mine digital assets powered exclusively by green energy. Today, HIVE builds and operates next-generation blockchain and AI data centers across Canada, Sweden, and Paraguay, serving both Bitcoin and high-performance computing (HPC) clients. HIVE's twin-turbo engine infrastructure-driven by Bitcoin mining and NVIDIA GPU-accelerated AI computing-delivers scalable, environmentally responsible solutions for the digital economy. For more information, visit hivedigitaltech.com, or connect with us on: X: https://x.com/HIVEDigitalTech YouTube: https://www.youtube.com/@HIVEDigitalTech Instagram: https://www.instagram.com/hivedigitaltechnologies/ LinkedIn: https://linkedin.com/company/hiveblockchain On Behalf of HIVE Digital Technologies Ltd. "Frank Holmes" Executive Chairman Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Forward-Looking Information Except for the statements of historical fact, this news release contains "forward-looking information" within the meaning of the applicable Canadian and United States securities legislation and regulations that is based on expectations, estimates and projections as at the date of this news release. "Forward-looking information" in this news release includes but is not limited to: the performance of the Company's existing operations, the construction of the Company's Phase 3 facility in Valenzuela, Paraguay and its potential specifications and performance upon completion, the timing of it becoming operational; business goals and objectives of the Company; the acquisition, deployment and optimization of the mining fleet and equipment; the continued viability of its existing Bitcoin mining operations; and other forward-looking information concerning the intentions, plans and future actions of the parties to the transactions described herein and the terms thereon. Factors that could cause actual results to differ materially from those described in such forward looking information include, but are not limited to: the inability to complete the construction of the Paraguay acquisition on an economic and timely basis and achieve the desired operational performance; the ongoing support and cooperation of local authorities and the Government of Paraguay; the volatility of the digital currency market; the Company's ability to successfully mine digital currency; the Company may not be able to profitably liquidate its current digital currency inventory as required, or at all; a material decline in digital currency prices may have a significant negative impact on the Company's operations; the regulatory environment for cryptocurrency in Canada, the United States and the countries where our mining facilities are located; economic dependence on regulated terms of service and electricity rates; the speculative and competitive nature of the technology sector; dependency on continued growth in blockchain and cryptocurrency usage; lawsuits and other legal proceedings and challenges; government regulations; the global economic climate; dilution; future capital needs and uncertainty of additional financing, including the Company's ability to utilize the Company's ATM Program and the prices at which the Company may sell Common Shares in the ATM Program, as well as capital market conditions in general; risks relating to the strategy of maintaining and increasing Bitcoin holdings and the impact of depreciating Bitcoin prices on working capital; the competitive nature of the industry; currency exchange risks; the need for the Company to manage its planned growth and expansion; the need for continued technology change; the ability to maintain reliable and economical sources of power to run its cryptocurrency mining assets; the impact of energy curtailment or regulatory changes in the energy regimes in the jurisdictions in which the Company operates; protection of proprietary rights; the effect of government regulation and compliance on the Company and the industry; network security risks; the ability of the Company to maintain properly working systems; reliance on key personnel; global economic and financial market deterioration impeding access to capital or increasing the cost of capital; share dilution resulting from the ATM Program and from other equity issuances; the construction and operation of facilities may not occur as currently planned, or at all; expansion may not materialize as currently anticipated, or at all; the digital currency market; the ability to successfully mine digital currency; revenue may not increase as currently anticipated, or at all; it may not be possible to profitably liquidate the current digital currency inventory, or at all; a decline in digital currency prices may have a significant negative impact on operations; an increase in network difficulty may have a significant negative impact on operations; the volatility of digital currency prices; the anticipated growth and sustainability of electricity for the purposes of cryptocurrency mining in the applicable jurisdictions; the inability to maintain reliable and economical sources of power for the Company to operate cryptocurrency mining assets; the risks of an increase in the Company's electricity costs, cost of natural gas, changes in currency exchange rates, energy curtailment or regulatory changes in the energy regimes in the jurisdictions in which the Company operates and the adverse impact on the Company's profitability; the ability to complete current and future financings, any regulations or laws that will prevent the Company from operating its business; historical prices of digital currencies and the ability to mine digital currencies that will be consistent with historical prices; an inability to predict and counteract the effects of pandemics on the business of the Company, including but not limited to the effects of pandemics on the price of digital currencies, capital market conditions, restriction on labour and international travel and supply chains; and, the adoption or expansion of any regulation or law that will prevent the Company from operating its business, or make it more costly to do so; and other related risks as more fully set out in the Company's disclosure documents under the Company's filings at www.sec.gov/EDGAR and www.sedarplus.ca. The forward-looking information in this news release reflects the Company's current expectations, assumptions, and/or beliefs based on information currently available to the Company. In connection with the forward-looking information contained in this news release, the Company has made assumptions about the Company's objectives, goals or future plans, the timing thereof and related matters. The Company has also assumed that no significant events will occur outside of the Company's normal course of business. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance, and accordingly, undue reliance should not be put on such information due to its inherent uncertainty. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether because of new information, future events or otherwise, other than as required by law. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272889
	2025-11-03 06:20 4mo ago	2025-11-03 01:00 4mo ago	Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting	stocknewsapi	MOLN
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present updated data from a Phase 1/2a trial of MP0533, a novel, multispecific T cell engager for acute myeloid leukemia (AML) patients, in a poster at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida, and online.

Showing 64,101–64,150 of 83,087 articles